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Abstract 
Buprenorphine is a promising medication for the treatment of opiate abuse. The 
pharmacology of buprenorphine has been studied in vitro using radioligand binding 
and e5S]GTPyS assays, and in vivo using assays of antinociception in rodents. A 
number of compounds with potential similar pharmacology have also been 
characterised. These are an iso-morphinan pyrrolidine derivative, and long-lasting 
14-aminomorphinones and codeinones, in particular clocinnamox (C-CAM), a pure !!-
antagonist and methoclocinnamox (MC-CAM), which has some agonist properties. 
Buprenorphine, a partial !!-agonist and K-antagonist, displays a unique bell-shaped 
dose-response curve in assays of antinociception in rodents. Pre-treatment of rats 
with the antagonist naltrexone shifted the ascending, but not the descending, phase of 
the dose-response curve. Investigation of the time-course of various doses of 
buprenorphine revealed that higher doses produced a rapid on- and offset of analgesia 
compared to lower doses, and this may explain the bell-shaped dose-response curve. 
The morphinan-pyrrolidine derivative, BUn, is shown to be a highly efficacious 
!!-opioid agonist in C6 glioma cells transfected with the cloned l1-opioid receptor. In 
the mouse warm water tail withdrawal assay Bun was 400 times more potent than 
morphine, and considerably longer-lasting. Bun exhibited delayed !!-antagonist 
action in both the warm water tail withdrawal and writhing assays, blocking the 
effects of a maximal dose of morphine for up to 2 weeks in the writhing assay. This 
compound may represent an improvement over buprenorphine for the treatment of 
opiate abuse. 
MC-CAM and a series of 3-substituted alkyl ether derivatives showed varymg 
efficacy in SH-SY5Y human neuroblastoma cells. All displayed high affinity for the 
!!-opioid receptor and with the exception of the iso-propyl ether, BU25, all the 
analogues displayed biphasic'binding profiles. BU25 was shown to be fully 
reversible in wash resistance assays. The results support 'pseudoirreversible' binding 
of these compounds to the !!-opioid receptor. 
Further in vitro studies of C-CAM confirmed !!-antagonist action but have also 
shown it to be an inverse agonist at the O-opioid receptor. Also identified as inverse 
agonists were 7-benzylidenenaltrexone (BNTX), and the peptide ICI 174,864. 
Treatment of C6 glioma cells with' pertussis toxin confirmed the presence of 
constitutive activity at the &- but not the Il-receptor. C-CAM did not inhibit basal 
e5S]GTPyS binding in C61l or C6 wild-type cells. 
Keywords: Opioid receptors, Il-opioid receptor, buprenorphine, antinociception, 
irreversible antagonist, clocinnamox CC-CAM), multiple binding sites, affinity, 
efficacy, SH-SY5Y cells, C6 glioma cells, inverse agonist, constitutive activity. 
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CHAPTER! 
GENERAL INTRODUCTION 
1.1 Historical Perspective 
The control of pain continues to be one of the most important and challenging aspects 
of medical care. The perception of pain may be categorised into two distinct 
subjective measures - a sensory component and an emotional component. Analgesic 
drugs may act by altering either or both of these elements. Although non-opioid 
analgesics can afford relief from mild to moderate pain, the opioid analgesics have the 
added advantage of reducing the emotional component, namely anxiety, tension, and 
fear. Therefore opioid analgesics can enable the patient to cope with relatively severe 
pain. However, neuropathic pain i.e. pain caused by damage to neuronal structures, 
often resulting in supersensitivity, does not respond well to the opioid analgesics. 
Opium, the latex obtained from the poppy Papaver somniferum, is the source of 
many pharmacologically important alkaloids. Morphine, named after Morpheus, the 
Greek God of dreams, was first isolated in 1803 by the German pharmacist Sertumer. 
Well reputed for its pain relieving properties, morphine rapidly established itself in 
medicine as an analgesic. 
HO 
Figure 1.1 The structure of morphine. 
Little was known about the mechanisms underlying the extensive pharmacological 
actions of morphine or other opiates until the 1970's. In 1971 Goldstein proposed 
that radiolabeled compounds might be used to demonstrate the existence of opioid 
receptors [Goldstein et aI., 1971]. Direct evidence that opiates are recognized by 
specific receptors came from binding studies in neuronal membranes [Pert & Snyder, 
1973; Wong & Hong, 1973, Simon et al., 1973]. These receptors were henceforth 
named opiate receptors. It soon became clear from experimental work that peptides 
may be endogenous ligands for the opioid receptor, and in 1975 Kosterlitz and co-
workers isolated two pentapeptides with opiate-like activity from porcine brain 
[Hughes et aI., 19751. These peptides were named methionine enkephalin (Tyr-Gly-
Gly-Phe-Met) and leucine enkephalin (Tyr-G1y-Gly-Phe-Leu), and differed only in 
the C-terminus amino acid. Both pep tides mimicked the action of morphine in in 
vitro bioassays by inhibition of electrically stimulated contractions of smooth muscle. 
Two other families of opioid peptides are the endorphins [Bradbury et aI., 19761, and 
the dynorphins [Goldstein et al., 19791. Both of these classes of peptides contain the 
Tyr-Gly-Gly-Phe-X sequence, where X = Leu or Met. 
In vivo studies of the wide range of actions of different opiates implied that 
multiple receptor types might be involved. Indeed in 1976 multiple receptor types 
were established [Martin et aI., 19761. The proposed receptor types were 11, at which 
morphine is the prototype agonist; K, at which ketocyclazocine is the prototype 
agonist, and cr, at which N-allylnormetazocine is the prototype agonist. Evidence for 
a fourth type of receptor came from Kosterlitz and his colleagues [Lord et aI., 19771. 
They discovered that in mouse vas-deferens and guinea-pig ileum morphine was not 
equipotent, nor were the enkephalins. Furthermore naloxone, an important opioid 
antagonist, was 10 times more potent in blocking opioid responses in the guinea pig 
ileum than in the mouse vas deferens. It was concluded that another type of receptor, 
christened S, predominated in the mouse vas deferens. cr-Receptors are insensitive to 
antagonism by naloxone and so are no longer classed as opioid receptors. Of the 
endogenous ligands, the enkephalins and endorphins bind to both the 11- and li-
receptors, whereas the dynorphins bind more selectively to the K-receptor. Other 
classes of peptides more recently discovered are the dermorphins and deltorphins, 
which were isolated from South American frog skin [Montecucchi et al., 1981, Kreil 
et al., 1989, Erspamer et al., 1989]. The dermorphins are highly selective for the 11-
receptor, and, as their name suggests, the deltorphins are highly selective for the li-
receptor. Also recently discovered are the endomorph ins I and 2 [Zadina et al., 1997] 
which are selective for the l1-receptor. The structures of the above named opioid 
peptides are shown in Fig. 1.2. 
The structure of the opioid receptors remained largely unknown until 1992, when 
two groups published reports of the expression cloning of cDNA encoding the li-
receptor from the neuroblastoma x glioma (NG I 08-15) cell line [Evans et aI., 1992; 
2 
Kieffer et aI., 1992). A rapid succession of molecular cloning reports were to follow: 
cloning of the rat l1-opioid receptor [Chen et al., 1993; Fukuda et aI., 1993; Wang et 
aI., 1993), the rat lC-opioid receptor [Chen et al., 1993b; Minami et aI., 1993; Li et al., 
1993; Meng et aI., 1993], the mouse lC-opioid receptor [Yasuda et al., 1993), and the 
rat O-opioid receptor [Fukuda et aI., 1993). The amino acid sequences of all three 
human opioid receptors have now been published, 11- [Wang et al., 1994),0- [Knapp 
et al., 1994; Simonin et aI., 1994), and lC- [Simonin et aI., 1995). 
Several research groups also reported the discovery of another, ORLl (opioid-
receptor-like) opioid receptor [Mollereau et aI., 1994, Bunzow et aI., 1994, Fukuda et 
al., 1994, Chen et aI., 1994, Wang et al., 1994). This receptor was found to be similar 
in sequence to the other opioid receptors, but shares greatest homology with the lC-
receptor. The pharmacological effects mediated by the ORLI receptor are not yet 
fully understood. It mediates the inhibition of adenylyl cyclase as do 11, 8, .and lC-
receptors, however it appears to also mediate anti-opioid actions, such as the 
inhibition of opioid induced analgesia. The endogenous ligand for the orphanin 
receptor is orphanin FQ, also known as nociceptin [Meunier et aI., 1995, Reinscheid 
et al., 1995). The opioid peptides and opiate alkaloids have low affinity for this 
receptor. 
3 
Met -enkephalin 
Leu-enkephalin 
~-Endorphin 
Dynorphin 1-17 
Dermorphin 
Deltorphin I 
Endomorphin 1 
Orphanin FQ 
Tyr-Gly-Gly-Phe-Met 
Tyr-Gly-Gly-PhecLeu 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Glu-Lys-Ser-Gln-
Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-lle-Ile-Lys-Asn-
Ala-His-Lys-Lys-Gly-Gln 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-Lys-Trp-
Asp-Asn 
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 
Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 
Tyr-Pro-Trp-Phe-NH2 
Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-
Ala-Asn-Gln 
Figure 1.2 The structures of various endogenous peptides for the opioid receptors. 
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1.2 Molecular Biology of the Opioid Receptor 
The opioid receptors belong to the superfamily of 7-transmembrane domain-spanning 
G-protein coupled receptors (7TM-GPCR's). Similar to the other members of this 
receptor class, the opioid receptorsconsist of a single polypeptide chain of 
approximately 400 amino acids in length, and possess 7 transmembrane a-helices (see 
Figure 1.3). The majority of 7TM-GPCR's share a degree of sequence homology 
with rhodopsin, the light-sensing molecule that binds the chromophore retinal: Since 
rhodopsin was the first G-protein coupled receptor to be cloned, a great deal of our 
understanding of the structure and function of this family of receptors is due to the 
detailed investigation of this molecule. It is believed that the ligand binding domain 
of the 7TM-GPCR's lies deep within one or more of the transmembrane segments, 
and site-directed mutagenesis has revealed that the third cytoplasmic loop is 
responsible for the binding of the G-protein [Bluml et ai., 1994]. The totally 
conserved arginine residue of the third intracellular loop has been implicated in the 
binding of the G-protein upon activation of the receptor [Schwartz, 1996]. 
There is a large degree of sequence homology between the three opioid rec.eptor 
types, 11, /), and K, with 57 % of the amino acid sequence conserved. The greatest 
sequence homology is seen in the first and sccond intracellular loops (90 %). The 
third intracellular loop shares approximately 78 % homology. Of the transmembrane 
domains, greatest sequence homology is seen in transmembrane domains II and III 
(84 % and 82 %) Transmembrane domains V and VII are also highly conserved (71 
%), however domains I, IV and VI show less homology. The amino and carboxy 
termini, and the extracellular loops, are not well conserved. The ORLI receptor 
shares the greatest sequence homology with the K-receptor due to its acidic second 
extracellular loop. 
The opioid receptors, like other 7TMD GPCR's, contain potential sites for 
phosphorylation by protein kinase enzymes. For example in the Il-opioid receptor 
phosphorylation of residues such as serine-263 or -365 or threonine-281 may be 
important in receptor desensitization leading to a reduced agonist response upon 
receptor occupation [Arden et aI., 1995]: The Il-opioid receptor also contains cysteine 
residues in positions 142 and 219 of the first and second intracellular loops which 
may be able to form a disulfide bridge. It is possible that this disulfide bridge controls 
receptor conformation changes and contributes to the overall structural stability of the 
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receptor [Simon & Groth, 1975, Smith & Simon, 1980, Ofri & Simon, 1992]. These 
cysteine residues are also present in 0 and 1C receptors. 
Point mutations of the receptor can also allow us to deduce which amino-acids in 
particular are responsible for the binding of Iigands to, and activation of, the receptor. 
For example replacing an aspartate residue at position 116 of transmembrane domain 
IT with an asparagine residue (and thus removing a carboxylate function) reduces the 
binding affinity of agonists, but not antagonists, for the receptor [Surratt et al., 1996]. 
Replacement of a serine residue at position 198 in transmembrane domain IV with a 
leucine residue converts agonist into antagonists as measured by coupling to adenylyl 
cyclase and K+ channels [Claude et al., 1996]. 
The construction of chimeric receptors offers another approach to the investigation 
of the role of specific regions of the opioid receptor. A chimeric receptor is one in 
which certain sequences of amino-acids are replaced by the sequence from another 
receptor subtype. The function of the chimeric receptor is then compared to the 
original receptor in order to elucidate the regions of the receptor involved in ligand 
specificity and G-protein coupling. For example, by this method it has been shown 
that a region of the third extracellular loop and transmembrane domain VI of the 0-
receptor is important for the binding of O-selective Iigands [Meng et aI., 1996]. 
It has been proposed that sUbtypes of the ~-receptor exist [Pastemak & Wood, 
1986]. The ~I receptor binds both the opiates and enkephalins with high affinity and 
the ~2 receptor, a lower affinity site, is responsible for the binding of the opiates only. 
Bare et al. [1994], reported the existence of a splice variant of the human ~-receptor, 
and Hollt and his colleagues [Zimprich et aI., 1995] reported the cloning and 
expression of an isoform of the rat ~-receptor. Splice variants therefore could 
represent ~-receptor sUbtypes. For further discussion of ~-receptor sUbtypes see 
Chapter 5, section 5.3. 
The existence of o-opioid receptor subtypes was first suggested by the groups of 
Portoghese and Porreca [Sofuoglu et aI., 1991, Jiang et al., 1991] based on in vivo 
antagonism studies using naltrindole and its analogues. This led to the proposal of 01 
and ~ sUbtypes. The peptides [D-Pen2,D-Pen5]enkephalin (DPDPE) and [D-Ala2,0-
Leu5]enkephalin (DADLE) are agonists at the 01 sUbtype and the peptide [0-
Ser,Leu5,Thr6]enkephalin (DSLET) is an agonist at the ~ subtype. Similarly 
selective antagonists exist for both subtypes, 7-benzylidenenaltrexone (BNTX) is an 
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antagonist at 01 and naltriben (NTB) is an antagonist at~. The question of IC-
receptor sUbtypes has also been raised [Dhawan et al., 1996]. Competition binding 
assays using brain membranes revealed biphasic inhibition curves suggesting that the 
aryl acetamide agonists CI977, U50,488H and U69,593 interact with ICI receptors 
whereas the benzomorphan ligands also interact with !C2 and !C3 sUbtypes. 
As yet however no cloning data is available to support the existence of any of the 
opioid receptor sUbtypes. 
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Figure 1.3 Cartoon showing the 7 -transmembrane spanning domains of the rat ~-opioid receptor. The amino-acid sequence data was obtained . 
from the Center for Opioid Research and Design. Department of Medicinal Chemistry. University of Minnesota. 
1.3 The G-Protein 
Attached to the inner surface of the cell membrane, G-proteins act on membrane 
bound intermediaries called effectors, either enzymes or ion channels. So called 
because of their interaction with the guanine nucleotides GDP and GTP, the G-
proteins represent the 'middle management' by relaying messages from the receptor 
to the effector. There are three main G-protein coupled effector systems: 
a) The adenylyl cyclase/cyclic AMP system 
b) The phospholipase C/inositol phosphate system 
c) The regulation of ion channels 
Each G-protein consists of three subunits: a, P, and r. Guanine nucleotides bind to 
the a-subunit. The P- and r- subunits exist as a tightly associated complex that 
functions as a single unit, and serves to anchor the G-protein to the membrane. In the 
resting state, the aPr trimer is bound by GDP and is uncoupled from the receptor (Fig. 
1.4). When an agonist binds to the receptor a conformational change in the receptor 
causes it to actively associate with the receptor-G-protein complex. This association 
causes an exchange of GDP for GTP, which in turn causes dissociation of the a-GTP 
complex from the Pr subunits. This a-GTP complex is the activated form of the G-
protein that diffuses into the membrane, thus relaying its message by activating or 
inactivating enzymes or ion channels. An intrinsic GTPase property of the a-subunit 
catalyzes the hydrolysis of the terminal phosphate of bound GTP to form GDP, 
thereby deactivating the a-subunit. The Ga-GDP complex then re-aSsociates with the 
Pr complex, which is then available for activation following agonist occupation of the 
receptor. 
Different types of G-protein exist which interact with different receptors and 
control different effectors. The four major families are Gs, Gq, G;lGo and G1Z, of 
which there are many subsets. The G-protein families are grouped together according 
to the degree of amino acid conservation of the a-subunit, and to a certain extent 
these families also have functional correlates in terms of receptor and effector 
interaction. The Gs and Gq families stimulate adenylyl cyclase whereas the G;lGo 
family inhibits this enzyme. Similarly the voltage-gated Caz+ channel is positively 
modulated by Gs and negatively modulated by Go. Opioid receptors couple to the 
G;lGo farriily. Most of the a-subunits of opioid receptorccoupled G-proteins are 
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substrates of one or both of two bacterial toxins, the toxin of Vibrio· cholera (cholera 
toxin) or Bordatella pertussis (pertussis toxin). In the presence of GTP, cholera toxin 
catalyses the ADP-ribosylation of a specific arginine residue of the Gs protein a-
subunit. This causes persistent activation of the G-protein and consequently 
uncontrolled activation of adenylyl cyclase. In the presence of ATP pertussis toxin 
ADP-ribosylates a specific cysteine residue of the Gi or Go a-subunit. The Gq family 
of G-proteins (which is not bacterial toxin sensitive) is known to stimulate 
phospholipase C, which catalyses the formation of the second messengers IP3 (inositol 
1,4,S-triphophate) and diacylglycerol. 
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Figure 1.4 Schematic diagram representing G-protein-mediated transmembrane signalling. Adapted from Rang & Dale, 1991. 
1.4 Pharmacology of Morphine and Related Compounds 
Structural features 
Although opioid Jigands vary In their size and molecular skeleton, certain 
pharmacophoric groups are essential for binding to the opioid receptors, namely an 
aromatic feature and a basic centre permitting protonation at physiological pH. The 
clinically useful opioids can be subdivided into groups according to their structure: 
polycyclic molecules of the morphine type, the benzomorphans e.g. pentazocine, the 
phenyl piperidines e.g. fentanyl and meperidine, and the acyclic diarylamines e.g. 
methadone. The structures of some of the opioids are shown in Fig. 1.5. 
Pharmacological actions - Effects on the Central Nervous System 
Analgesia - Morphine mediates analgesia via its actions at spinal and supraspinal 
sites in the central nervous system (see Fig. 1.6). The opioid analgesics selectively 
inhibit various nociceptive reflexes and cause profound analgesia when injected 
intrathecally, by inhibiting transmission of nociceptive impulses through the dorsal 
horn of the spinal cord. Injection of morphine directly into the periaqueductal gray 
and nucleus raphe regions also produces analgesia by enhancing the activity of the 
descending aminergic pathways that inhibit the processing of nociceptive information 
in the spinal cord. &. and K-opioid receptors and their agonists also contribute to 
analgesia. I)-Agonists mediate antinociception by directly inhibiting the actions of 
selective agonists on the release of substance P from nociceptive afferent neurons. In 
addition there is evidence that supraspinal I)-sites mediate antinociCeption [Mathiasen 
& Vaught, 1987, Heyman et aI., 1988]. Antinociceptive effects of K-agonists have 
been shown in rhesus monkeys and rodents [Porreca et aI., 1987, France et al., 1994], 
and appear to be mediated via spinal receptor sites. There is a degree of controversy 
surrounding the existence of supraspinal K-sites which mediate antinociceptive effects 
[Porreca et al., 1987, MilIan et aI., 1989]. 
Euphoria - Euphoria is an important component of the analgesic effect of 
morphine, since the patient is relieved of the distress associated with the sensation of 
pain. The activation of dopaminergic neurons that project to the nucleus accumbens 
is postulated to be a critical element in the reinforcing effects of opioids, and 
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therefore, the euphoria induced by these compounds. However, K-agonists inhibit the 
firing of dopaminergic neurons and thus produce dysphoria. 
Respiratory depression - The primary mechanism behind respiratory depression 
involves a reduction in responsiveness of the respiratory centres in the brainstem to 
increased arterial PC02• All phases of respiratory activity, including tidal exchange, 
minute volume, and rate, are depressed. There is some evidence to suggest that 
respiratory depression is mediated through the ~2 sub-population of receptors, [Ling 
et ai., 1983, 1985] due to the ability of the ~l selective antagonist naloxonazine to 
antagonize the anti nociceptive, but not respiratory depressive, effects of morphine in 
rats. However, Gatch et ai., [1996], have shown that in rhesus monkeys naloxonazine 
antagonized both the respiratory depressive and antinociceptive effects of the ~­
agonist levorphanol to a similar degree, suggesting that the antinociceptive and 
ventilatory effects of levorphanol are mediated via a similar population of receptors. 
Again there is controversy surrounding the ability of li- and K-opioid receptor agonists 
to cause respiratory depression [Wang et al., 1993, Hepburn et al., 1997, Shook et al., 
1990]. 
Cough reflex - Morphine acts as an antitussive agent by blocking the cough reflex 
centre in the medulla. There is no relationship between respiratory depressive effects 
of morphine and the suppression of coughing. Codeine is one of the few opioid 
analgesics used as an antitussive agent. Effective doses are generally lower than those 
required to produce analgesia. 
PupiUary constriction - This is a centrally-mediated effect caused by activation of 
the nucleus of the oculomotor nerve by ~- and K-receptors. 
Nausea and vomiting - Nausea and vomiting can occur in up to 40 % of patients 
recei ving morphine. This is caused by a direct action on the chemoreceptor trigger 
zone (CTZ) of the medulla, where chemical stimuli of many kinds may initiate 
vomiting. There is also an increase in vestibular sensitivity, which contributes to the 
nausea. These effects of morphine usually disappear with repeated administration. 
Endocrinological effects - Morphine acts on the hypothalamus to cause release of 
antidiuretic hormone (ADH), which leads to a decrease in urinary output. 
Conversely, K-agonists inhibit the release of ADH thus causing diuresis. 
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Effects on the gastrointestinal system 
Morphine causes an increase in the resting tone of the stomach, small intestine and 
large intestine. In the stomach there is decreased motility and a delay in emptying of 
gastric contents to the small intestine. There is a delay in digestion of food in the 
small intestine, and in the large intestine, propulsive peristaltic contractions are slower 
or even abolished after morphine administration. As a result of these actions, 
constipation occurs, which may be severe. Morphine also causes a decrease in biliary 
secretions and an increase in biliary tract pressure. 
Effects on the cardiovascular system 
At therapeutic doses morphine does not have a marked effect on the cardiovascular 
system. At higher doses morphine can cause bradycardia and hypotension via a direct 
action on the medulla. Hypotension is also a result of peripheral vasodilatation and 
reduced peripheral resistance. Morphine induces histamine release, which may 
contribute to hypotension, but it also decreases the reflex vasoconstriction caused by 
increased peoz. 
Metabolism 
Morphine undergoes considerable first pass metabolism and so is not as effective 
orally compared to intravenous or intramuscular injection. The majority of metabolic 
transformation occurs in the liver. Morphine is conjugated at the 3-0H and/or the 6-
OH position with glucoronide to give either the monoglucoronide or the 
diglucoronide. The conjugates are excreted in the urine and the bile. 
Tolerance and dependence 
Tolerance can be defined as an increase in the dose of drug needed to produce a given 
pharmacological effect. Tolerance occurs to most of the pharmacological effects of 
morphine, including analgesia, euphoria, and respiratory depression. Little tolerance 
develops to the gastrointestinal effects and pupillary constriction. The exact 
mechanisms behind the development of tolerance still remain elusive, although it is 
believed that the chronic effects of opioids in vitro involve the following changes at 
the cellular level: 
a) desensitisation - the receptor becomes uncoupled from the effector such as 
adenylyl cyclase hence giving a reduction in agonist affinity. 
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b) down-regulation - receptors are removed from the cell surface (internalised), 
passing into the cell where they are either degraded or later recycled to the cell 
surface. This results in a loss of receptor number or binding sites, and although 
this has been demonstrated for opioids acting on various cell lines, attempts to 
show this in brain homogenates from tolerant animals have failed. 
c) Adaptive changes in effector systems - it has been suggested that tolerance might 
be associated with an increase in activity of adenylyl cyclase within the cell. 
Chronic opioid treatment results in a reduction of opioid inhibition of adenylyl 
cyclase, which gradually returns to normal. Removal of opioid agonist then 
results in an increase of cAMP production, known as a 'cAMP overshoot'. 
Continued use frequently results in physical and psychological dependence; 
physical dependence manifested by a characteristic abstinence syndrome induced on 
abrupt withdrawal of the opioid. Diarrhoea, fever, chills, vomiting, abdominal cramps 
and lacrimation are common signs of withdrawal. Peak withdrawal symptoms occur 
around 36 - 72 hr, and usually disappear after 8 - 10 days. Some symptoms may 
persist for weeks. Re-administration of morphine (or other opioid agonist) will 
abolish the abstinence syndrome. 
Psychological dependence is more complex, but plays an important part in 
compulsive drug-taking behaviour. Behavioural models have been developed to 
study this phenomenon, in particular self-administration assays using rhesus monkeys 
or rats whereby the reinforcing effects of the drugs can be studied. 
For a detailed review of the pharmacology of morphine and other opioids see 
Martin, 1984. 
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Figure 1.5 The structures of various opioid ligands. 
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Figure 1.6 Diagram representing the descending control pathway, showing postulated 
sites of action of opioids on pain transmission. Opioids excite neurons in 
the periaqueductal grey (PAG) and in the nucleus reticularis 
paragigantocellularis (NRPG), which in turn project to the nucleus raphe 
magnus (NRM). From the NRM, enkephalin-containing neurons exert an 
inhibitory effect on transmission in the substantia gelatinosa of the dorsal 
horn. Opioids can also have a direct action on the dorsal horn. Adapted 
from Rang & Dale, 1995. 
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1.5 Opioid Addiction: The Drug Abuse Problem 
Opioid abuse is one of the most significant public health problems facing our society 
today. Heroin, an acetylation product of morphine that causes intense craving and 
physical dependence, is the most commonly abused opioid. The National Household 
Survey on Drug Abuse in the U.S.A reported that in 1996 an estimated 2.4 million 
people use heroin at some stage in their lives. According to the 1997 bulletin of drug 
misuse statistics for Scotland, 66 % of new attenders at drug services in the U.K. for 
the period of 6 months up to March 1997 were using heroin. In Scotland alone the 
percentage of people using heroin as their main drug of abuse has increased from 39 
% in 199211993 to 49 % in 1996/1997. In addition reports of HN infection amongst 
injecting drug users has risen from 744 in 1987 to 1176 in 1997. More than one third 
of the AIDS cases registered in 1997 were due to parental drug abuse. 
Street heroin is most commonly found as a brownish powder or as 'black tar 
heroin', which, as its name suggests, is of a black sticky consistency. It can be 
injected, sniffed or snorted, and smoked. Street heroin is cut with a variety of 
different substances, brown sugar, taIc, flour, cocoa, quinine, or procaine (a local 
anaesthetic). The average street purity of heroin is now approximately 5 %. Many 
addicts do not know the strength of their obtained heroin and so are at risk from 
overdose, which unfortunately is a frequent occurrence in the drug scene. Death 
occurs as a result of respiratory depression. Long-term effects of heroin use include 
collapsed veins, bacterial infections, abscesses, and arthritis due to immune reactions 
to batch contaminants. Sharing of injection equipment also leads to the transmission 
of AIDS. 
Prior to the development of substitution medication for the treatment of opioid 
abuse, addicts were treated by abrupt withdrawal or gradual discontinuation of their 
drug. Although addicts were institutionalized for prolonged periods of time, and the 
programs were successful during the residential phase, frequent relapse upon 
discharge occurred. It be.came clear that a new type of approach to opioid abuse 
treatment was required. 
The ideal drug abuse treatment would be to alleviate the craving, prevent 
withdrawal symptoms, and avoid relapse. At present there are three substances 
approved by the Food and Drug Administration (FDA) of the V.S which are used to 
treat heroin abuse - methadone, LAAM (levo-alpha-acetylmethadol) and naltrexone. 
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Clonidine, which is used to treat hypertension, is also sometimes used in the initial 
stages of detoxification. Both methadone and LAAM are j!-opioid receptor agonists, 
whereas naltrexone is an j!-antagonist and c10nidine is an a-adrenergic agonist. 
Methadone, a synthetic opioid, was first reported as a successful substitution 
therapy for opioid dependence in 1965 by Dole & Nyswander. It is currently the most 
widely used treatment and has been shown to decrease illicit drug use and criminal 
activity as well as preventing further spread of HIV amongst intravenous drug users 
[Gerstein & Harwood, 1990]. Unfortunately methadone is not without disadvantages. 
Daily visits to the clinic for supervision of methadone ingestion are inconvenient for 
the patient and also interfere with the ability of the person to become truly integrated 
with a typical drug-free lifestyle. The introduction of take-home methadone resulted 
in the s~le and illicit use of this treatment drug. It too causes physical dependence and 
has abuse potential comparable to that of heroin. For this reason methadone treatment 
programs are stricti y controlled. 
LAAM, (Ievo-alpha-acetylmethadol), an analogue of methadone, was formally 
approved as a pharmacotherapy in the U.S in 1993. The effects of LAAM have been 
described as being more 'subtle' than those of methadone. LAAM has a slower onset 
of action, and a longer-lasting effect, therefore clinic visits can be reduced to three or 
four times weekly. The lack of take-home doses of LAAM may aid in preventing 
creation of a street market for the drug. 
The opioid antagonist naltrexone is also used to treat opioid dependence, although 
this type of compound can precipitate severe withdrawal symptoms and so is normally 
restricted to either treating opioid overdose, or is used as a continuing treatment drug 
after the patient has been drug-free for one to two weeks. 
One of the most promising alternative medications currently being considered for 
clinical use is the partial Il-opioid receptor agonist buprenorphine, which has 
pharmacological properties that appear to be ideal for the treatment of heroin abuse. 
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1.6 Buprenorphine: A Novel Treatment for Opioid Abuse? 
Buprenorphine is currently marketed as Temgesic in the U.K (Buprenex in the 
U.S.A), and is used as an analgesic for the treatment of moderate to severe pain. At 
present buprenorphine is being developed as a daily-dosing pharmacotherapy for the 
treatment of opioid abuse. It is anticipated that the Food and Drug Administration of 
the U.S.A will grant approval for this indication in the near future. Indeed 
buprenorphine is already used in France for the treatment of opioid dependency 
[Henrion, 1997]. 
Buprenorphine, a derivative of the morphine alkaloid thebaine, was first 
synthesized and tested by Bentley & Hardy [1967]. Despite the need for further 
characterization of this drug, there ar~ a number of unique pharmacological features 
of buprenorphine that suggest it to be a viable treatment for heroin or other opioid 
dependencies. It has a high affinity for the ~-receptor with a low intrinsic activity; 
therefore it is mixed partial ~-agonist/antagonist. The partial agonist nature of 
buprenorphine confers a ceiling of effect thus limiting the possibility of overdose, and 
increasing the margin of safety. Although buprenorphine has a high degree of 
Iipophilicity it has a long duration of action, due to extremely slow receptor 
dissociation kinetics [Hambrook & Rance, 1976]. Hence buprenorphine also has the 
ability to block any subsequently self-administered opioid. 
Another unique feature of buprenorphine that has perplexed researchers for several 
years is its characteristic biphasic dose-response curve that is observed in a variety of 
in vivo assays, particularly those of antinociception. This will be discussed in more 
detail in Chapter 3. 
1.6.1 in vitro studies 
in vitro data has shown that buprenorphine has high affinity in the nM range for the ~, 
Band lC binding sites, although with somewhat reduced affinity for the O-binding site 
[Grayson et al., 1991]. The order of potency of buprenorphine for the binding sites is 
lCl=IDB>lCz. These affinity results correspond with the data obtained in vivo by 
Richards & Sadee [1985a]. Interestingly, a comparison of the affinities of 
buprenorphine for the recently available cloned opioid receptors reveals that it has 
highest affinity for the B-receptor [Reisine & Bell, 1993]. 
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Phannacokinetic analysis of the binding of eH]buprenorphine to opioid receptors 
has shown that it has a slow receptor association and dissociation as compared to 
other opiate ligands [Boas & Villiger, 1985, Hambrook & Rance, 1976]. Indeed the 
dissociation of buprenorphine is biphasic with an initial rapid phase followed by a 
very slow phase where approximately 50 % of the tritiated ligand still remains bound. 
This persistent binding probably accounts for the long duration of action in vivo (in 
excess of 6 hr) that does not parallel its plasma half-life time of approximately 3 - 5 
hr. Villiger & Taylor [1981] also reported that large concentrations of naloxone were 
required to displace eH]buprenorphine, and in studies using rhesus monkeys it has 
been shown that the discriminative effects of buprenorphine are prevented, but not 
reversed, by naltrexone [France et al., 1984]. 
More recently techniques have been developed which enable the measurement of 
agonist efficacy in vitro. Two such techniques are the use of stimulation of 
e 5S]GTPyS binding [Traynor & Nahorski, 1995], and the inhibition of forskolin-
stimulated cyclic AMP [Law et al., 1983]. It has now been shown using the 
e 5S]GTPyS assay that buprenorphine exhibits partial agonist activity in membranes 
prepared from rat C6 glioma cells expressing the cloned rat Il-opioid receptor (see 
Section 4.2, Chapter 4) and in membranes prepared from SH-SY5Y cells [Traynor & 
Nahorski, 1995]. There is limited information regarding the interaction of 
buprenorphine with the Il-receptor. Recently it has been shown using the e5S]GTPyS 
assay that buprenorphine has no agonist activity at the cloned rat Il-receptor expressed 
in C6 glioma cells [Lee et aI., submitted for publication] nor at the o-receptor in 
NG108-15 cells [our laboratory, unpublished observations]. However, buprenorphine 
has been shown to inhibit the accumulation of cAMP in human embryonic kidney 
(HEK) 293 cells expressing the cloned mouse O-receptor [Blake et al., 1997]. 
Buprenorphine shows very low efficacy at the cloned K-receptor expressed in Chinese 
hamster ovary (CHO) cells [Zhu et al., 1997]. 
1.6.2 In vivo studies 
The first experiments using buprenorphine were carried out by Martin et al. [1976] 
using the chronic spinal dog preparation. This was closely followed by the work of 
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Cowan et al. [1977a,b] who reported a thorough pharmacological characterization of 
the compound. From these studies came several valuable findings: 
a) In the mouse writhing assay and the rat tail pressure test buprenorphine was 25 -
40 times more potent than morphine. 
b) The dose-response curve for buprenorphine was biphasic in rodent tail withdrawal 
assays; test of catalepsy, and gastrointestinal transit assays. 
c) Buprenorphine induced locomotor activity in mice, showed an antitussive action 
in guinea-pigs, reduced heart rate but had no significant effect on arterial blood 
pressure in conscious rats and dogs, and increased arterial Peo2 and P02 values in 
conscious rats. 
d) It suppressed urine output in water loaded rats. 
e) Buprenorphine antagonized the antinociceptive effects of morphine in the rodent 
tail withdrawal assay, but not the rat tail pressure test. 
f) It precipitated signs of abstinence in morphine-dependent mice and monkeys but 
not in rats. 
g) Withdrawal symptoms were relatively low in monkeys chronically treated with 
buprenorphine. 
From this early work it was clear that buprenorphine was showing partial agonist 
actions at the Il-opioid receptor. This was also supported by the work of Hayes et al. 
[1986], who showed that pre-treatment of rats with the irreversible Il-antagonist ~­
funaltrexamine, (~-FNA), resulted in the dose-response curve for buprenorphine 
having a decreased slope and maximal anti nociceptive effect in the paw pressure test. 
There is now substantial evidence that buprenorphine has antagonist properties at 
the K-receptor. For instance the dose-response curve for bremazocine-induced 
diuresis in rats is displaced to the right following administration of buprenorphine 
[Ri chards & Sadee, 1985b]. There are very few reports concerning the effects of 
buprenorphine at the O-receptor, in part due to the lack of appropriate 
pharmacological tools. With the advent of naltrindole, the o-selective antagonist 
[Portoghese et al., 1988], studies of the interaction of buprenorphine with the 0-
receptor should be easier. 
The most interesting feature of the animal pharmacology of buprenorphine must 
surely be the characteristic bell-shaped dose-response curve, which was first observed 
in rat tail withdrawal assay [Cowan et aI., 1977a]. Having perplexed researchers for 
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many years. the cause of this unique effect still remains to be determined. To date it 
has been explained in terms of a two-receptor model (non-competitive autoinhibition) 
[Sadee et al.. 19821. a two-point attachment to a single receptor [De Lean et al .• 
19791. and cooperative receptor interactions [Dum & Herz. 1981]. Perhaps the most 
widely accepted model is that of non-competitive autoinhibition whereby agonist 
effects are mediated by one receptor. at the lower dose range. and a second inhibitory 
receptor. at the higher dose range. counteracts the effects of the first. Sadee et al. 
[19831 proposed that the second inhibitory site may be o..mediated. but as yet no 
evidence has been found to support this. Speculation has also arisen as to the second 
phase of the curve being !C-mediated [Rothman et al.. 19951. however the possibility 
of the !Cl receptor being responsible has been eliminated [Leander. 1983. Rothman et 
al.. 19951 although the !C2 receptor still remains to be investigated. Studies have 
shown that the non-selective antagonists naloxone and naltrexone can shift the dose-
response curve to the right symmetrically. therefore both antagonists must have 
similar affinity for both sites and are able to interact with these sites in a competitive 
manner. 
Another interesting aspect of the pharmacological actions of buprenorphine is that 
its antinociceptive action can easily be prevented. but not reversed. by opioid 
antagonists [France et al .• 19841. This is indicative of an irreversible component of 
receptor binding. This is in accordance with in vitro studies where it was found that 
eH1buprenorphine dissociation from the receptor was extremely slow and a portion of 
the tritiated ligand remained persistently bound. 
Opioid agonists typicall y produce physical dependence upon chronic 
administration. It was therefore surprising to discover that buprenorphine failed to 
produce the manifestations of physical dependence when administered to animals for 
prolonged periods of time [Cowan et al .• 1997a1. It is generally believed that the tight 
interaction of buprenorphine with the opioid receptor maintaining a long duration of 
action helps to counteract the sudden biochemical imbalance on sudden withdrawal of 
the drug. 
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1.6.3 Clinical studies 
An important feature of buprenorphine as a pharmacotherapy for opioid abuse is its 
ability to block the physiological effects of subsequently administered opioid agonists 
such as heroin. Early studies with opioid addicts indicated that buprenorphine 
blocked the effects of subsequently administered doses of morphine [Jasinski et al. 
[1978], and hydromorphone [Bickel et al., 1988a], presumably due to its partial 
agonist nature and long-lasting receptor interaction. 
As regards to its clinical efficacy and promotion of treatment compliance, it has 
been reported that a comparison of fixed doses of buprenorphine and methadone 
showed that buprenorphine was as effective as methadone for the treatment of opioid 
dependence [Johnsone et aI., 1992, Bickel et aI., 1988b]. Another study comparing 
the efficacy of methadone and buprenorphine in a flexible dosing procedure also 
recommended that buprenorphine was as efficacious as methadone [Strain et al., 
1994]. However a study by Kosten et al. [1993] reported that methadone may be 
more effective. As a substitution therapy it may be that buprenorphine is ideal for 
those addicts who have a less chronic form of opioid addiction, whereas those more 
resistant to dependence treatment may be better served by methadone. 
Reports concerning physical dependence caused by chronic treatment with 
buprenorphine indicate that compared to methadone, buprenorphine does not induce 
physical dependence to the same degree [Jasinski et al., 1978, Fudala et aI., 1990]. 
Heroin and methadone-dependent subjects given buprenorphine as a substitution 
therapy did not experience a typical methadone abstinence syndrome, but noted mild 
withdraw~1 symptoms during the transition period. Subsequent termination of 
buprenorphine precipitated a mild abstinence syndrome that peaked after 3 days 
[Jasinski et aI., 1983, 1984]. Challenge with naloxone was found to be not nearly as 
effective ID precipitating abstinence in subjects treated chronically with 
buprenorphine as compared to morphine dependent subjects [Jasinski & Preston, 
1995]. 
Unfortunately, the fact that buprenorphine does have significant reinforcing effect 
and appears to maintain treatment compliance gives the compound potential for 
abuse. In several countries, where the use of buprenorphine is less restricted, there 
have emerged reports of the abuse of buprenorphine. For example in Scotland [Gray 
et aI., 1988, Robertson & Bucknell, 1986], in England [Strang, 1985], and in Australia 
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and New Zealand [Quigley et al., 1984, Harper, 1983]. This led to the development 
of a buprenorphine/naloxone combination product marketed in New Zealand. The 
route of administration is an important consideration where abuse liability is 
concerned, as it was reported that sublingual preparations were being injected 
intravenously [Sakol et al., 1989]. It is believed that the non-injectable sublingual 
preparation is the better drug-delivery system [Jasinski et ai., 1989]. 
From the evidence thus far it would seem that buprenorphine would be an effective 
medication for the treatment of opiate dependence. Given its morphine-like 
subjective effects, combined with the low level of physical dependence and mild 
withdrawal syndrome, buprenorphine appears to be acceptable to opiate-dependent 
subjects. Its unusual, yet promising, pharmacological profile has also now provided a 
basis from which opioid researchers can continue to develop novel treatments for drug 
abuse. 
25 
1.7 General Aims 
The preceding discussion suggests that buprenorphine may be useful as an alternative 
pharmacotherapy for the treatment of opioid abuse. Buprenorphine has unique 
pharmacological characteristics which include mixed partial Jl-agonist/K-antagonist, 
long duration of action and the ability to block subsequently self-administered 
opioids. Despite its promising profile, buprenorphine still may not be ideal, in 
particular the degree of reinforcing effect may not be sufficient to maintain certain 
addicts in treatment programs. The aim of this work is to study buprenorphine and a 
number of its analogues in order to ascertain the mechanisms behind their unique 
pharmacology and to determine if the existing characteristics of buprenorphine can be 
further improved. To achieve this a combination of in vitro and in vivo techniques 
will be used as follows: 
a) study the antinociceptive profile of buprenorphine in the rat warm water tail 
withdrawal assay, 
b) examine the pharmacology of a novel morphinan pyrrolidine derivative at both 
the cellular level and in vivo using mice, and assess its potential as a treatment 
drug, 
c) examine the binding profile and efficacy at the Jl-opioid receptor of analogues of 
clocinnamox, a long-lasting 3-substituted cinnamoylamino compound, using 
homogenates prepared from SH-SY5Y cells and C6 glioma cells transfected with 
the cloned rat Jl-opioid receptor, 
d) evaluate constitutive activity at theJl- and O-opioid receptors in C6 glioma cells 
and investigate the inverse agonist effects of clocinnamox at these receptors. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Radiochemicals 
eH]DAMGO ([D-Alaz, MePhe4 , Gly(oli]enkephalin) (54 Ci mmor\ 
eH]diprenorphine (45 Ci mmor' and 58 Ci mmor'), eH]DPDPE ([D-Penz, D-
Pen5]enkephalin) (39 Ci mmor'), eH]naltrindole (33 Ci mmor'), eH]U69,593 (54 Ci 
mmor' ) and e5S]GTPyS (1250 Ci mmor') were all purchased from DuPont NEN 
Boston, MA, USA. 
2.1.2 Chemicals 
Acetic acid, EDTA (ethylenediaminetetraacetic acid), Folin & Ciocalteu's phenol 
reagent, GDP (guanosine diphosphate), GTPyS (guanosine triphosphate), GppNHp 
(guanylylimidophosphate), HEPES (N-[2-hydroxyethyl]piperazine-N' -[2-
ethanesulfonic acid], MgCh.6HzO, MgS04.7HzO, pertussis toxin, Trizma base 
(tris[hydroxymethyl]aminomethane) were purchased from Sigma Chemical Co., St. 
Louis, MO, USA. 
CaCh, KCI, KzHP04.3HzO and NaCI were purchased from Mallinckrodt, St. Louis, 
MO,USA. 
DMSO (dimethylsulfoxide) was from Fisher Scientific, Pittsburgh, PA, USA. 
NaHC03 was from Columbus Chemical Industries, Inc., Columbus, WI, USA. 
UltimaGold liquid scintillation fluid was from Packard Bioscience, Groningen, 
Holland. 
2.1.3 Drugs 
The following drugs were generous gifts from the National Institute on Drug Abuse, 
Rockville, MD, USA: buprenorphine HC!, cIocinnamox (C-CAM), fentanyl HCI, 
methadone HC!, methocinnamox (M-CAM), methocIocinnamox (MC-CAM), 
naloxone HCI, naltrexone HC!, and SNC80. 
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7-Benzylidenenaltrexone (BNTX), D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 
(CT AP), naltrindole (NTI) and nor-binaltorphimine (nor-BNI) were a kind gift from 
NIH, Bethesda, MD, USA. 
Bremazocine was from Sandoz, Basel, Switzerland. 
BW373U86 was from Burroughs Wellcome, Research Triangle Park, NC, USA. 
~-Funaltrexamine was purchased from Research Biochemicals Inc., SEMAT, SI. 
Albans, UK. 
ICI 174,864 was purchased from Tocris Cookson, Ballwin, MO, USA. 
Morphine sulfate was purchased from Mallinckrodt, SI. Louis, MO, USA.· 
All of the BU (Bristol University) compounds were synthesized by John Lewis and 
co-workers at the Department of Chemistry, University of Bristol, UK. 
2.1.4 Cell culture media 
Dulbecco's Modified Eagle Medium, Minimum Essential Medium, foetal calf serum, 
trypsin, EDTA, and genetic in were all from Gibco Life Sciences, Grand Island, NY, 
USA. 
Sterile DMSO was from Sigma Chemical Co., SI. Louis, MO, USA. 
2.1.5 Buffers 
The composition of the KrebslHEPES buffer used to maintain whole cells during 
wash resistant binding studies was (mM): NaCI (118), NaHC03 (25), KCI (4.7), 
CaCh (2.5), MgS04.7H20 (1.2), KH2P04 (1.2), Glucose (11.7) and HEPES (10), pH 
7.4. 
The buffer used in e5S]GTPyS assays was (mM): HEPES (20) MgCI2.6H20 (10) and 
either NaCI (100) for standard assays or KCI (100) for assays using inverse agonists. 
The pH was adjusted to 7.4 with NaOH. 
The buffer used in membrane binding studies was Trizma base (50 mM) acidified 
with HCI to pH 7.4. 
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2.1.6 Animals 
Male Dunkin-Hartley guinea pIgs (250 - 500g) were bought from David Hall, 
Newchurch, Burton-on-Trent, UK. 
Male NIH Swiss mice (25 - 30 g) and male Wistar rats (250 - 300 g) were purchased 
from Harlan Sprague Dawley Inc., Indianapolis, IN, USA. Mice were housed in 
groups of 10 - 12 and rats were housed in groups of 3 in it temperature-controlled 
room maintained on a 12 hr light-dark cycle. Food and water were available ad 
libitum until the time of the experiment. For in vivo experiments each subject was 
tested only once and studies were carried out in accordance with the Declaration of 
Helsinki and with the Guide for Care and Use of Laboratory Animals as adopted and 
promulgated by the National Institutes of Health. The experimental protocols were 
approved by the University of Michigan's University Committee on the Use and Care 
of Animals. 
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2.2 Methods 
2.2.1 Cell culture and membrane preparation 
The SH-SY5Y human neuroblastoma cell line was kindly donated by Dr. D. Lambert, 
Department of Anaesthesia, Leicester University, UK. The cells were grown in 
Minimum Essential Medium (MEM) supplemented with 10 % foetal calf serum, 2.5 
I1g mr' amphotericin B (fungizone), 50 I1g mr' penicillin/streptomycin, and 250 I1g 
mr' L-glutamine at 37°C in a humidified 5 % CO2 atmosphere. 
C6 glioma cells transfected with either the cloned rat 11- or &-receptor were a kind 
donation from Dr. Huda Akil, Mental Health Research Institute, University of 
Michigan, MI, USA. Cells were cultured under a 5 % CO2 atmosphere in Dulbecco's 
modified Eagle's medium supplemented with 10 % fetal calf serum. For subculture 
one flask from each passage was grown in the presence of I mg mr'Geneticin. Cells 
used for experiments were grown in the absence of Geneticin with no significant 
reduction in receptor number. 
Once cells had reached confluency they were harvested in HEPES (N-[2-
hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid], 20 mM pH 7.4)-buffered saline 
containing I mM EDT A, dispersed by agitation and collected by centrifugation at 
1600 rpm (Centra CL2 centrifuge, International Equipment Co.). The cell pellet was 
suspended in 50 mM Tris-HCI buffer pH 7.4, and homogenized with a tissue tearor 
(Biospec Products). The resultant homogenate was centrifuged for 15 min at 18000 
rpm at 4°C (Beckman centrifuge model J2-21) and the pellet collected, resuspended 
and recentrifuged. The final pellet was resuspended in 50 mM Tris-HCI buffer pH 
7.4; separated into 0.5 ml aliquots (0.75 - 1.0 mg protein) and frozen at -80°C. 
For wash resistance studies whole cell suspensions were incubated In 
KrebslHEPES buffer (pH 7.4) in the presence of drug for I hr at 37°C. Both treated 
and control cells were washed four times to remove any unbound drug. Cell 
membranes were then prepared as described above. 
For pertussis toxin (PTX) treatment cells were incubated with lOO ng mr' PTX for 
24 hr prior to harvesting. 
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2.2.2 Preparation of brain homogenates 
Animals were decapitated and the brain removed, weighed and homogenised in Tris-
HCl buffer for 15 sec using a Polytron homogeniser. After centrifugation (35,OOOg, 
15 min, 4°C) the pellet was resuspended in 10 times the volume of Tris buffer and 
incubated at 37°C for 30 min to enable dissociation of endogenous ligands. The 
homogenate was re-centrifuged as above and the pellet was finally resuspended in 
Tris buffer to give a known concentration of approximately 1 :60 w/w (original weight 
of wet tissue). 
Protein concentration for both cell membrane and mouse brain membrane 
preparations was determined by the method of Lowry et al. [1951], using a bovine 
serum albumin standard. 
2.2.3 Ligand binding assays 
An important method for the study of receptors and their ligands is the radioligand 
binding assay. A great advantage of this method is that it does not require the 
receptor of interest to be purified; relatively crude tissue preparation will suffice. 
However there also exists a second binding component, namely non-specific binding, 
where the radioligand binds to non-receptor tissue, the test tubes, or filters. The total 
specific binding is therefore determined by the difference between the binding in the 
absence of, and the binding in the presence of, a large excess of an unlabelled, 
competitive ligand. In most instances this ligand will be naloxone, which has high 
affinity for the opioid receptors. 
The specificity of opioid receptor binding is demonstrated by the findings that 
compounds which show opiate-like activity generally have a much higher affinity for 
opioid binding sites than non-opioids. Pharmacological observations have established 
that stereospecificity plays a major role in opioid receptor binding; for instance the (-) 
isomer of some alkaloids can compete for the binding site 1000 times more 
effectively than the (+) isomer. 
The specific binding of an opioid is characterized by two parameters: 
a) the affinity constant of the ligand (or its reciprocal, the dissociation constant). 
b) the number of binding sites (Bmax). 
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When examining a radio ligand, saturation analysis enables us to obtain both 
parameters. When examining a non-radiolabeled ligand its affinity constant is 
obtained through competition studies. This is done by measuring the ability of the 
ligand to displace a radiolabeled opioid with a known affinity constant. The affinity 
of the unlabelled ligand can be estimated either as an ICso or as a Ki . These two 
values are related by the Cheng and Prusoff equation: 
Ki = ICso / (I + ([L]/ K.J)) 
where [L] = concentration of radioligand, ICso = concentration of unlabelled ligand at 
which 50 % inhibition of binding of radioligand is achieved, K.J = dissociation 
constant of radiolabeled ligand. 
Although Ki values provide a more accurate assessment some assumptions have to 
be made - one assumes that the radio ligand is labeling a single site and that all the 
assumptions regarding mass law hold. No assumptions need to be made regarding 
ICso values; unlike the Ki values these are dependent on the radioligand used and its 
concentration. 
Hill plots can be used to assess binding site heterogeneity in competition studies. 
Hill coefficient values determine if there is a possibility that the radioligand is 
labeling more than one site. A value of unity suggests one site, however a value of 
less than I is indicative of receptor heterogeneity. 
Competition binding assays - C6 glioma cell membranes (30 - 60 Ilg protein), SH-
SY5Y cell membranes (100 - ISO Ilg protein), or mouse/guinea-pig brain membranes 
(I mg mr! protein) were incubated at 25°C in 50 mM Tris-HCI buffer, pH 7.4 for I hr 
with radiolabelled ligand and varying concentrations of unlabeledligand to give a 
final volume of I m\. Non-specific binding was defined with 10 IJM naloxone. The 
reaction was terminated by filtering the samples through glass fiber filters (Whatman 
GF/C, Schleicher and Schuell #32) mounted in a Brandel 24 well harvester. The 
filters were subsequently washed 3 times with ice-cold Tris-HCI, pH 7.4 and 
radioactivity determined by scintillation counting (Beckman LS6800 scintillation 
counter) after addition of 3 ml of liquid scintillation fluid. ICso and Ki values were 
determined using GraphPad Prism, version 2.01 (GraphPad, San Diego; CA), using 
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KD values of 0.2 nM for eH]diprenorphine and 1.0 nM for eH]DAMGO, 
eH]DPDPE, and eH]U69,593 as determined by saturation assay. 
Saturation binding assays - Membrane homogenates (I mg mrl) were incubated at 
25°C for 1 hr with varying concentrations of tritiated ligand (10 - 0.005 nM) in the 
presence of either water (control) or 10 J.!M naloxone to determine total specific 
binding. Th reaction was terminated by rapid filtration and filters subjected to liquid 
scintillation counting as above. Binding capacities (Bmax) and equilibrium 
dissociation constants (KD) were calculated from non-linear regression using 
GraphPad Prism, San Diego, CA, USA. 
[35 S]GTP'f.) binding - Membrane homogenates were incubated for I hr at 30°C in 
the presence of eSS]GTPyS (100 pM), GDP (10 J.!M for SH-SY5Y cell homogenates, 
30 J.!M for C6 glioma cell homogenates) and various concentrations of unlabeled 
ligand. Maximal stimulation was determined using fentanyl (10 J.!M) for Il-receptor 
studies, and SNC80 (( + )-4-[(aR)-a-((2S,5R)-4-allyl-2,5-dimethyl-l-piperazinyl)-3-
methoxybenzyl]-N,N-diethylbenzamide, 10 J.!M for O-receptor studies). The tissue 
was again rapidly filtered and filters subjected to liquid scintillation counting as 
before. The amount of stimulated eSS]GTPyS binding is given as a percentage of the 
maximal stimulation evoked by either fentanyl or SNC80. The ECso values (effective 
concentration producing a 50 % maximal response) were calculated using GraphPad 
Prism. 
2.2.4 In vivo studies - Wann water tail withdrawal assay 
A modification of the warm water tail-withdrawal assay procedure of Janssen et al. 
[1963] was employed. Each mouse was placed in a cylindrical restraint with the tail 
fully exposed. Approximately one-third of the distal portion of the tail was immersed 
in water at 50°C, and latency to complete tail-withdrawal was measured. Baseline 
latencies were typically 2 - 4 sec. Only mice meeting this criterion were used. 
Agonists and vehicles were administered intraperitoneally (i.p.) (26112 gauge needle, 
Becton Dickinson and Co.) and except for time course studies, latencies were 
measured 25 min later. Antagonists were administered by the intraperitoneal route at 
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the following times prior to agonist: M-CAM, I hr; naltrindole, 15 min; nor-BNI, 24 
hr. A cut-off latency of 20 sec was used to prevent injury to the tail. Mice that did 
not respond within this time were removed and assigned a score of 20 sec. 
Experiments using rats were essentially the same, except that rats were wrapped in 
a surgical towel instead of being placed in a restraint. Baseline latencies were 
typically 4 - 6 sec. All drugs were administered subcutaneously (s.c.). 
The percent maximum possible effect (% MPE) at each point was calculated 
according to the following formula: 
% MPE = (test latency - baseline latency) 
(20 - baseline latency) 
ED50 and 95 % confidence limits were determined using linear regression 
according to the method of Tallarida and Murray (1981, procedure 8). Dose-effect 
curves were considered to be significantly different when the range of. values 
contained within the 95 % confidence limits did not overlap. 
Acetic Acid Induced Writhing Assay - The acetic acid induced writhing assay 
[Koster et ai., 1959] was used as another method for determining antinociception. 
Mice received agonist or vehicle subcutaneously, and except for the time course, this 
was followed 20 min later by 0.6 % acetic acid (0.4 ml per animal) given i.p. Mice 
were placed in individual Plexiglass boxes (18 x 28 x 13 cm) for observation. Five 
minutes after injection of acid an observation period began where the number of 
writhes during a 5 min period were counted. A writhe is typically a wave of 
contraction of the abdominal muscles followed by an extension of the hind legs. 
Control values were determined for each new batch of mice. Data were calculated as 
mean number of writhes ± S.E.M. for each treatment group. Student's t-test was 
employed to determine significant differences between treatment groups. 
Measurement of Locomotor Activity - Experiments were performed with a Digiscan 
Micro System, Omnitech Electronics, Columbus, OH, USA, with four transparent 
Plexiglas activity monitor cages (46 x 24 x 18.5 cm) each placed in a soundproof 
chamber. A Plexiglass plate drilled with 8 to 12 airholes covered each cage. 
Locomotor activity in the horizontal plane was measured with a set of 16 photocells 
projecting horizontal infrared beams 2.5 cm apart and 2.4 cm above the cage floor. 
One unit or count of activity registered each time a light beam was broken. Data were 
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automatically recorded and processed by the Digiscan Micro Analyzer. Individual 
points were then compared for significant differences using Student's Hest, GraphPad 
Prism. 
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CHAPTER 3 
AN INVESTIGATION OF THE BELL-SHAPED DOSE-
RESPONSECURVE OF BUPRENORPHINE 
3.1 Introduction 
Buprenorphine is a promising novel pharmacotherapy for the treatment of opiate 
abuse [Bickel & Amass, 1995]. It has a unique pharmacological profile, which may 
offer superiority over currently existing treatment drugs such as methadone or 
LAAM. As discussed in section 1.6, buprenorphine produces morphine-like 
subjective effects, although because it is a Il-partial agonist it can block the euphoria 
caused by higher efficacy opiates [Jasinski et al., 1978]. In addition the unpleasant 
and often dangerous side effects associated with traditional full Il-opioid agonists, 
such as respiratory depression, are limited with the use of buprenorphine [Jasinski et 
al., 1978], and only a mild withdrawal syndrome is observed on cessation of its use 
[Fudala et al.,1990]. Therefore the use of buprenorphine in treatment programs can 
provide the addict with a relatively comfortable and rapid detoxification [Jasinski et 
aI., 1978; Mello et aI., 1982]. Additionally buprenorphine has a long duration of 
action due to extremely slow dissociation kinetics, which provides for the attenuation 
of the effects of any subsequently self-administered heroin or other opioid. 
In many in vivo assays using either rodents or primates, buprenorphine exhibits a 
unique biphasic dose-response relationship, for example in the mouse hot plate assay 
[Tyers, 1980], the rat charcoal meal [Cowan et aI., 1977b], and the monkey tail dip 
assay [Woods et al., 1992]. In assays of low noxious stimulus such as the late phase 
flinching of the formalin paw test buprenorphine is fully efficacious and exhibits a 
normal sigmoidal dose-response relationship. 
Current literature attempts to explain the unusual biphasic relationship in terms of 
non-competitive auto inhibition and the existence of two functionally related opioid 
receptor subtypes [Sadee et aI., 1982, Rance et al., 1980, Cowan, 1992]. As yet, 
however, no definitive explanation for this mechanism has been reported. In order to 
elucidate the mechanism behind the unusual phenomenon, a study of the 
antinociceptive effect of buprenorphine in rats using the warm water tail withdrawal 
assay at 50°C was carried out. In particular, time-courses of antinociceptive effects 
of various doses of buprenorphine were determined. This set of experiments test the 
hypothesis that the biphasic dose-response is dependent upon the time-course of the 
drug. The ability of the antagonist naltrexone to inhibit the dose-response curve was 
also investigated. 
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3.2 Results 
In the rat wann water tail withdrawal assay at 50°C buprenorphine acted as a partial 
agonist (Fig. 3.1), and compared to morphine, EC50 4.2 mg kg"1 (95 % Cl = 3.1 - 5.7 
mg kg· l ) it was 140 times more potent, EC50 0.03 mg kg-I (95 % Cl = 0.01 - 0.08 mg 
kg-I). Buprenorphine showed a bell-shaped dose-response curve with maximal effect 
(68.8 ± 9.3 % MPE) reached at a dose of 0.32 mg kg-I. At higher doses a plateau 
effect is reached at approximately 35 % MPE. 
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Figure 3.1 Cumulative dose-response curves of morphine and buprenorphine in the 
rat wann water tail withdrawal assay (50°C). Each point represents mean 
± S.E.M for at least 6 rats. 
Time-courses of the anti nociceptive effects of various doses of buprenorphine are 
shown in Figs. 3.2 and 3.3. Lower doses appear to have antinociceptive action for up 
to 8 - 12 hr (Fig. 3.2), whereas the higher doses retain some antinociceptive activity 
12 hr after administration (Fig. 3.3.). 
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Figure 3.2 Time course of antinociceptive effect of buprenorphine, 0.032 mg kg" and 
0.1 mg kg". Values represent mean ± S.E.M for 6 rats. 
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Figure 3.3 Time course of antinociceptive effect of buprenorphine, 0.32 mg kg" and 
1.0 mg kg". Values represent mean ± S.E.M for six rats. 
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A closer evaluation of the initial time-course of effect revealed that at a higher 
dose (1.0 mg kg-I) there was a rapid onset of antinociception, reaching a near maximal 
effect within 15 min of administration (Fig. 3.4). This was followed by a rapid offset 
of antinociception, and after 1.5 hr the antinociceptive effect had decreased to 25.5 % 
MPE. Conversely at lower doses (0.1 - 0.32 mg kil) the onset of antinociception was 
much slower, reaching peak effect at I hr after administration of 0.1 mg kg-I and 30 
min after administration of 0.32 mg kg-I. The offset of antinociception was also 
considerably slower with the lower doses of buprenorphine. 
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Figure 3.4 Initial time-course of antinociceptive effect of various doses of 
buprenorphine. Values represent mean ± S .E.M for 6 rats. 
A plot of % MPE against dose of buprenorphine for the different testing time 
intervals (i.e. the time elapsing between administration of drug and test of 
antinociception), revealed that the bell-shape of the dose-response curve was 
dependent upon the testing time interval (Fig. 3.5). Measurement of antinociception 
15 min after administration does not show a biphasic curve over the dose range tested, 
whereas anti nociceptive measurements taken 30 min or I hr after administration show 
a bell-shape dose-response. The peak effect also occurs at different doses depending 
on the testing time interval. Employing a testing time interval of I or 1.5 hr results in 
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the peak effect occurring at 0.1 mg kg'!, whereas the peak effect occurs at 0.32 mg 
kg'! if a testing time interval of 30 min is used. 
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Figure 3.5 Plot of dose-effect curve for buprenorphine using different testing time 
intervals. Testing time interval is defined as the time elapsing between 
administration of drug and test of antinociception. Values represent mean 
± S.E.M for 6 rats. 
Due to the ability of the larger dose of buprenorphine (1.0 mg kg'!) to produce a 
rapid on-set, followed by a rapid off-set, of antinociception, a possible hypothesis to 
explain this was that the subsequent rapid decline in antinociceptive effect was a 
result of receptor desensitization. Rats were pre-treated with 1.0 mg kg'! 
buprenorphine and after 1.5 hr, at which time the anti nociceptive effect had decreased 
to a plateau level of approximately 35 % MPE, rats were given a second dose of 1.0 
mg kg'! buprenorphine (Fig. 3.6). Fifteen min after the second dose there was only a 
slight increase in antinociception to 51 %, which was maintained for at least 60 min. 
A dose-response to fentanyl, a high efficacy Jl-agonist, was also determined after pre-
treatment with 1.0 mg kg'! buprenorphine for 1.5 hr (Figs. 3.7 and 3.8). Even after 
normalization of values to account for the antinociception caused by buprenorphine it 
can be seen that there was not a significant shift in the dose-response to fentanyl (Fig. 
3.8). 
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Figure 3.6 Antinociceptive effect of a 1.0 mg kg-1 dose of buprenorphine 
administered after pre-treatment of rats with 1.0 mg kg-1 buprenorphine 
for 1.5 hr. Each point represents mean ± S.E.M for 6 rats. 
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Figure 3.7 Dose-effect curve of fentanyl after pre-treatment of rats for 1.5 hr with 1.0 
mg kg- 1 of buprenorphine. Each point represents mean ± S.E.M for 6 rats. 
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Figure 3.8 Dose-effect curve of fentanyl following pre-treatment with 1.0 mg kg·1 
buprenorphine for 1.5 hr, as in Fig. 3.7. In this graph the baseline level of 
antinociception caused by the buprenorphine pre-treatment has been 
subtracted from the fentanyl curve. Each point represents the mean ± 
S.E.M for 6 rats. 
In order to examine the effect of the antagonist naltrexone on the bell-shape dose-
response curve of buprenorphine, rats were pre-treated with various doses of 
naltrexone for 15 min prior to administration of buprenorphine (Fig. 3.9). It can be 
seen that naltrexone is able to shift the ascending, but not the descending, phase of the 
dose-response curve. The magnitude of the shift increased with increasing dose of 
naltrexone. The EC50 for buprenorphine in the presence of 0.1 mg kg- I naltrexone 
was 0.14 mg kg· I (95 % Cl = 0.12 - 0.16 mg kg· l ) and in the presence of 1.0 mg kg·1 
was 0.81 mg kg· I (95 % Cl = 0.49 - 1.35 mg kg· I ). Pre-treatment with 10 mg kg· I 
naltrexone almost completely flattened the dose-response curve, hence the ECso could 
not be calculated. 
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Figure 3.9 Dose-response curve of buprenorphine following pre-treatment with 
various doses of naItrexone for 30 min. A cumulative dosing procedure 
was employed. Values again represent mean ± S.E.M for at least 6 rats. 
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3.3 Discussion 
The bell-shaped dose-response curve of buprenorphine has puzzled researchers for 
many years. The above study was carried out in an attempt to shed further light on 
the mechanism behind this unusual effect. Initial experiments using a cumulative 
dosing paradigm in the rat warm water tail withdrawal assay at 50°C confirmed that 
buprenorphine was a partial agonist, and indeed showed a biphasic dose-response 
relationship with maximal effect occurring at 0.32 mg kg· l . This is consistent with 
previous findings in rats using the radiant heat tail-flick assay [Rance et aI., 1980], the 
tail withdrawal assay at 55°C [Cowan et aI., I 977a] , and the electrically induced 
vocalization test [Dum & Herz, 1981]. 
A time-course of various doses of buprenorphine revealed that the highest dose 
tested, I mg kg· l , a dose that forms part of the descending phase of the dose-response 
curve, produced a rapid, near maximal anti nociceptive effect which appeared to occur 
within 15 min of administration. This was followed by a rapid offset of 
antinociceptive effect. The opposite was observed with lower doses of 
buprenorphine, i.e. a slow onset of antinociception followed by an equally slow offset. 
Dum & Herz [1981] reported similar results in the rat electrically induced 
vocalization test, i.e. larger doses of buprenorphine produced a rapid peak of 
antinociception whilst the lower doses showed a slower onset of antinociceptive 
activity. Interestingly, in the present study, following administration of a larger dose 
of buprenorphine the rapid decline in antinociceptive activity did not reach zero % 
MPE, but rather reached a plateau around 25 % which was maintained for several 
hours. This also correlates with the data of Dum & Herz. A subsequent plot of 
buprenorphine dose vs % MPE for each different testing interval (the time elapsing 
between administration and test for antinociception) showed that the biphasic curve 
was dependent upon this time interval. Testing for antinociception 15 min after 
administration did not reveal a bell-shaped dose-response curve due to the fact that at 
higher doses of buprenorphine an initial, rapid, peak of antinociception occurred. The 
dose of buprenorphine producing peak antinociception also changed depending upon 
testing time interval. For example, if the test for antinociception was to be employed 
30 min after buprenorphine administration the peak effect would be seen at 0.32 mg 
kg· l . However, if the test of antinociception were to be employed 1.5 hr after 
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administration, the peak effects would be seen at 0.1 mg kg-I. A likely explanation 
for the rapid decline in antinociceptive effect seen at high doses of buprenorphine is 
receptor desensitization. Alternatively, buprenorphine is interacting with a second 
site on the receptor that modulates the agonist actions of the first site, and this second 
interaction is more rapid with a high dose of buprenorphine. Both of these 
explanations will be discussed in greater detail below. 
Blake et al. [1997], have shown that acute buprenorphine treatment of HEK 293 
cells expressing the cloned mouse l1-opioid receptor resulted in a desensitization 
reaction characterized by a reduced ability of morphine and buprenorphine to inhibit 
forskolin-stimulated cyclic AMP accumulation. Buprenorphine is known to have 
very slow kinetics of dissociation resulting in a long-lasting interaction with the 
receptor [Boas & Villiger, 1985, Hambrook & Rance, 1976]. Additionally, it is 
difficult to reverse the effects of buprenorphine once established [Cowan et al., 
1977a, France et aI., 1984]. Therefore, despite the fact that buprenorphine is only a 
partial agonist, the 'pseudoirreversible' binding may be responsible for a rapid 
desensitization of the l1-opioid receptor, as this persistent binding. could cause 
functional desensitization. If this were so, then it should be testable by administration 
of a further dose of l1-agonist when the agonist effects of buprenorphine had declined. 
Administration of a second 1.0 mg kg-I dose of buprenorphine following pre-
treatment for 1.5 hr with an initial 1.0 mg kg-I dose did not result in any significant 
increase in anti nociceptive effect over and above that which remained. The ability of 
a high efficacy l1-opioid agonist, fentanyl, to evoke an anti nociceptive response was 
unchanged. This would argue against desensitization. 
It is possible that the decreased ability of buprenorphine and morphine to inhibit 
cAMP accumulation following pre-treatment of cells with buprenorphine in the study 
by Blake et al. [1997] is simply a result of being unable to wash buprenorphine from 
the receptors. Buprenorphine is a highly lipophilic molecule and for this reason is 
known to persistently bind to the l1-receptor [Hambrook & Ranee, 1976]. The 
inability of a second dose of buprenorphine to evoke a significant antinociceptive 
response may be because the initially administered buprenorphine has formed a tight 
interaction with the receptor and is therefore simply antagonizing itself. However, if 
this were the case then one would expect the antinociceptive effect of fentanyl to be 
blocked also. The fact that fentanyl is a high efficacy l1-opioid agonist, thus requiring 
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less receptor occupancy to evoke a full response, could account for its ability produce 
an antinociceptive effect. The receptors may not be fully saturated after treatment 
with 1.0 mg kg-· buprenorphine as there has been conflicting evidence as to what dose 
of causes receptor saturation [Dum & Herz, 1981, Rance et al., 1980]. But again we 
would still expect to see a shift in the dose-response curve to fentanyl following 
buprenorphine pre-treatment. A possible explanation is that fentanyl is binding to a 
different receptor site. A recent study by Heerding et al. [1994] has suggested that 
buprenorphine has different Jl-receptor binding requirements than other Jl-agonists. 
Site directed mutagenesis experiments revealed that mutation of key amino-acids 
required for morphine, DAM GO and levorphanol binding did not affect the binding of 
buprenorphine. Additionally Bot et al. [1988] found that mutation of a histidine 
residue in transmembrane VI of the Jl-receptor greatly reduced the binding affinity of 
diprenorphine and buprenorphine, but only a small shift in the affinity of naloxone 
and morphine for the receptor was observed. Recent results in our lab have also 
suggested that the oripavines may have different binding modes which are not altered 
by Na+ ions, and are different from morphine and fentanyl [Lee et al., submitted for 
publication]. This may explain why the production of antinociception by fentanyl 
was unaffected by buprenorphine pre-treatment as the two compounds may have 
different receptor interactions. It may be useful to examine the effects of another Jl-
agonist with structural similarity, such as etorphine, following buprenorphine pre-
treatment. 
An alternative explanation for the bell-shaped dose-response curve is that 
buprenorphine exerts its agonist and antagonist effects at different receptors, and that 
it accesses the inhibitory receptors at higher doses. Evidence exists that over the 
agonist dose-range buprenorphine produces its effects via the Jl-receptor [Martin et 
aI., 1976, Cowan et al., 1977a,b, Ward & Takemori, 1983], although more recently it 
has been shown that buprenorphine inhibits cyclic AMP accumulation in COS cells 
and HEK 293 cells transfected with the cloned mouse &-opioid receptor [Kong et al., 
1993, Bot et aI., 1998]. The findings that buprenorphine has agonist action at the &-
receptor, however, are not consistent, for example in our laboratory it was found that 
buprenorphine did not stimulate the binding of e5S]GTP'yS in C6 glioma cells 
transfected with the cloned rat &-receptor [Lee et al., submitted for publication], nor in 
membranes prepared from NG108-15 cells (unpublished observations). Indeed it has 
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been reported that pre-treatment of mice with the O-selective antagonist naltrindole or 
the K-selective antagonist nor-binaltorphimine (nor-BNI) had no effect on the 
antinociception produced by buprenorphine in the radiant heat tail flick assay [Kamei 
et al., 1997], and there is evidence that buprenorphine acts as a K-antagonist in vivo 
[Richards & Sadee, 1985b, Negus & Dykstra, 1988]. As yet the identity of the 
receptor whereby buprenorphine might exert its antagonist actions is largely 
unknown. There are a number of explanations involving different receptors that could 
account for the unusual antagonist actions of higher doses of this drug. Firstl y, as 
proposed by Cowan et al. [1977], Rance et al. [1980], and Sadee et al. [1982], non-
competitive autoinhibition may be occurring. Buprenorphine exerts its agonist 
actions at one receptor site, and then at higher doses buprenorphine binds to the 
second, lower affinity site that counteracts the effects of the first, higher affinity site. 
It has been suggested that this second site may be a O-opioid receptor site [Sadee et 
al., 1983] although this has never been confirmed. Another suggestion comes from 
DeLean et al. [1979], who proposed that buprenorphine forms a two-point attachment 
to a single receptor. Dum & Herz [1981] have also postulated that the biphasic curve 
may be a result of cooperative receptor interaction at higher occupancy, of a 
homogenous population of receptors. 
In our experiments, at doses of both 0.1 and 1.0 mg kg-I, naltrexone shifted the 
ascending, but not the descending, phase of the dose-response curve. This is 
inconsistent with the previous findings and suggests differences between single 
dosing and cumulative dosing paradigms. In the studies by Dum & Herz [1981], 
Cowan [1992], and Rance et al. [1980], it was found that either naloxone or 
naltrexone shifted the both phases in a parallel fashion, implying that naltrexone and 
naloxone are competitive antagonists at both sites. However, both Dum, Herz, and 
Cowan employed a single dosing procedure as opposed to a cumulati ve dosing 
procedure used in our study and the study of Rance et al. Furthermore, it is 
interesting to note that statistical analysis of the parallel shift of the dose-response 
curve generated by Rance et al. showed only one point to be significantly different. 
The inability of naltrexone to shift the descending arm of the curve suggests that 
naltrexone is not a competitive antagonist at this site. This implies that the second site 
of buprenorphine action is one that is inaccessible to naltrexone. Aside from its 
agonist action, the only major difference between the binding of naltrexone and 
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buprenorphine to the opioid receptors is that buprenorphine can bind to the Il-opioid 
receptor in a 'pseudoirreversible' manner [Lewis, 1985]. It is therefore possible that 
the second phase of the dose-response curve represents this long-lasting interaction of 
buprenorphine with the Il-receptor. It may be that there is not a distinct second site 
involved, but rather a subsequently induced receptor conformational change. This 
may relate to the irreversible nature of buprenorphine such that naloxone cannot 
reverse the effects of buprenorphine once established. 
Further evidence that the second phase of buprenorphine dose-response is 
connected to 'pseudoirreversible' It-binding comes from a paper published by 
Husbands et al. [1988], who report that the 14-cinnamoylamino codeinone 
methoc1ocinnamox (MC-CAM), a partial It-agonist [Woods et aI., 1995] and other 
alkyl ether derivatives with It-agonist activity exhibit biphasic dose-response curves 
similar to buprenorphine. It has been shown that MC-CAM is a long-lasting 
'pseudoirreversible' It-antagonist [Woods et al., 1995, Butelman et al., 1996]. 
We propose that the descending, antagonist phase of the bell-shaped dose-response 
curve of buprenorphine is due to the onset of 'pseudoirreversible' binding and a 
subsequent induction of an antagonist conformation of the It-receptor (Fig. 3.10). It is 
possible that the development of this tight interaction is slower than the initial binding 
interaction that enables agonist activation. This accounts for the fact that at higher 
doses a peak of antinociception is observed but is followed by a rapid decrease as 
higher receptor occupancy enables the change of more receptors into the antagonist 
conformation. This second conformation of the receptor would, however, appear to 
allow some agonist action resulting in the persistent 25 - 35 % antinociception seen in 
our experiments. Indeed it may also be that there is a percentage of receptors which 
are not susceptible to the buprenorphine-induced receptor conformation change. At 
lower doses, the inhibition of agonist activity induced by· the change in receptor 
conformation has a much slower time course due to overall less receptor occupancy. 
Once a certain level of receptor occupation is reached and the secondary, long-lasting 
inhibitory interaction of buprenorphine occurs, the inhibitory interactions of 
naltrexone are simply overcome. This model may also address the Issue of 
differences seen between single and cumulative dosing procedures. Under a 
cumulative dosing paradigm buprenorphine is given more time to form its secondary 
interaction with the receptor, and so ultimately more of the receptors undergo the 
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confonnation change within the time limits of the experiment. However a single 
dosing procedure does not allow this, hence there are never enough receptors 
occupied tightly enough by buprenorphine to block the competitive actions of 
naltrexone. 
From this and previous studies we can see that the biphasic nature of the 
buprenorphine response is one of great complexity that clearly warrants further study. 
It may be of great importance to detennine the exact mechanism by which 
buprenorphine exerts its unique effects as ultimately this may be the key to the 
development of novel pharmacotherapies for the treatment of opioid abuse. 
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Figure 3.10 Schematic representation of buprenorphine binding to the Il-opioid 
receptor. Phase A shows the receptor in its normal resting state. Phase 
B shows buprenorphine binding to the receptor and causing an agonist 
response. The binding of buprenorphine at this first stage is reversible. 
Phase C depicts the receptor adapting an antagonist conformation as the 
binding of buprenorphine becomes 'irreversible' with time. Fentanyl 
interacts with a different site on the receptor. 
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CHAPTER 4 
BU72: A NOVEL, HIGHLY EFFICACIOUS, OPIOID AGONIST 
WITH LONG-LASTING ANTAGONIST PROPERTIES 
4.1 Introduction 
A mentioned previously in sections 1.6 and 3.1, buprenorphine is a promising 
alternative to methadone and LAAM for the treatment of opioid abuse. Much 
research has focused around the mixed agonist/antagonist profile of buprenorphine 
[Cowan et aI., 1977a, 1977b; Bickel & Amass, 1995], with the belief that a 
combination of these characteristics produces an efficacious compound for patient 
compliance, together with the ability to attenuate any subsequently self-administered 
heroin or other opioid. 
Despite its desirable pharmacological characteristics, buprenorphine is not ideal as 
a treatment drug. In particular the degree of reinforcing effect afforded by 
buprenorphine is less than methadone, and may not be sufficient to maintain certain 
opiate addicts in treatment [Fudala et al., 1995]. With this in mind we have sought to 
characterize and develop more efficacious and longer lasting analogues of 
buprenorphine. A promising candidate is the novel morphinan pyrrolidine derivative, 
BUn (Fig. 4.1) [Husbands & Lewis, 1995]. BU72 is an iso-morphinan derivative, 
bridged 6,14- with an etheno group and 5,7- with an aminobenzyl group which forms 
a substituted pyrrolidine ring. When compared structurally to buprenorphine the 
phenyl ring corresponds to the t-butyl group but is attached ~- to C7 whereas the t-
butyl group in buprenorphine is attached [X- to C7• BU72 has a piperidine N-methyl 
group in contrast to the N-cyclopropylmethyl group of buprenorphine which is more 
usually associated with opioid antagonism [Lewis, 1995]. 
In the following study the pharmacology of BUn is characterized, both in vitro 
itnd in vivo using mice. The binding profile of BU72 has been studied in mouse brain 
and Il-efficacy has been determined in a rat glioma cell line stably expressing the 
cloned Il-opioid receptor [Thompson et al., 1993]. The antinociceptive actions of 
BUn were studied in the mouse warm water tail-withdrawal assay at 50°C, and the 
acetic acid-induced writhing assay. The results show that BUn is a highly 
efficacious Il-agonist with delayed Il-receptor antagonist action, and may, therefore, 
exhibit a better pharmacological profile for a treatment drug than either methadone or 
buprenorphine. 
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Figure 4.1. The structure of BUn. 
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4.2 Results 
4.2.1 In vitro studies 
Competition binding assays 
As can be seen in Table 4.1 the morphinan-pyrrolidine BUn displayed high affinity 
in the sub-nanomolar range for 11-, 0-, and K-opioid binding sites in mouse brain 
membranes as measured by the inhibition of eHlDAMGO, eHlDPDPE, and 
eH]U69,593 binding respectively. BUn also showed high affinity for the l1-opioid 
binding site in C6 glioma cell membranes as measured by the Ki derived from the 
inhibition of eHldiprenorphine binding (Table 4.2 and Fig. 4.2). This affinity was 
similar to buprenorphine but lOO-fold higher than morphine or methadone. Hill 
coefficients for the binding of BUn, buprenorphine, methadone, and morphine to C6 
glioma cell membranes and mouse brain membranes were all close to unity. 
Table 4.1 
Ki (nM) 
11 ([3H1DAMGO) 0 (eH1DPDPE K (eH]U69,593 
Bun 0.36 ±0.07 0.46 ± 0.09 0.15 ± 0.06 
Ki values for the inhibition of eH1DAMGO, eH1DPDPE, and 
eH1U69,593 binding in mouse brain membranes. Data represent mean 
Ki ± S.E.M. for three experiments performed in duplicate. 
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Figure 4.2 Displacement of eHjdiprenorphine (0.2 nM) specific binding by BUn, 
buprenorphine, morphine and methadone in membranes prepared from 
C61l glioma cells. Each data point represents mean ± S.E.M for at least 
three experiments performed in duplicate. SB = specific binding. 
Drug Ki (nM) 
BUn 0.06 ± 0.02 
Morphine 6.33 ± 2.55 
Methadone 5.85 ± 2.39 
Buprenorphine 0.12 ± 0.03 
Table 4.2. Binding potencies of BUn, morphine, methadone, and buprenorphine at 
the Il-opioid receptor in C6 glioma cell membranes. Data are expressed as 
the mean Ki ± S.E.M. for three determinations performed in duplicate. 
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Bun acted as a potent full agonist in the eSS]GTI'yS assay as compared to the /l-
opioid receptor agonist fentanyl, affording an ECso value of 0.05 ± 0.01 nM and a 
maximal stimulation of 70.4 ± 23.6 fmol eSS]GTI'yS bound mg'l protein (Fig. 4.3). 
This represented 116 % of the fentanyl response. Morphine and methadone afforded 
ECso values of 30.10 ± 4.20 nM and 77.60 ± 18.90 nM, and maximal stimulations of 
96 % and 105 % of the fentanyl response respectively. Buprenorphine was a partial' 
agonist representing 33 % of the fentanyl response with an ECso value of 0.21 ± 0.19 
nM. 
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Figure 4.3 Stimulation of eSS]GTI'yS binding by BUn, buprenorphine, morphine 
and methadone in membranes of C6J.l glioma cells. Values shown are 
mean ± S .E.M for at least three experiments performed in duplicate. 
55 
4.2.2 In vivo studies 
1. Agonist Actions - Antinociceptive effect 
Bun administered i.p. produced dose-dependent antinociception in the mouse warm 
water tail-withdrawal assay at 50°C (Fig. 4.4). BUn was approximately 400 times 
more potent than morphine in this assay, affording an ED50 value of 0.07 mg kg-I 
(95% Cl = 0.05 - 0.09 mg kg-I) as compared to 27.14 mg kg-I (95 % Cl = 40.92 -
17.99 mg ktl) for morphine. At single doses administered s.c. BU72 also produced 
potent, dose-dependent, antinociception in the mouse acetic acid-induced writhing 
assay (Fig. 4.5). 
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Figure 4.4 Antinociceptive effects of cumulative doses of morphine and Bun in the 
mouse warm water tail withdrawal assay at 50°C. Values represent the 
mean ± S.E.M. of all mice tested (n=5) at each particular dose of drug. 
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Figure 4.5 Antinociceptive effect of morphine and BUn in the mouse acetic acid-
induced writhing assay. Values represent mean ± S.E.M for 6 mice 
Control writhing = 11.4 ± 1.9 writhes. 
To determine the receptor through which BUn was exerting its antinociceptive 
action in the tail withdrawal assay, selective antagonists were used (Fig. 4.6). Pre-
treatment of mice i.p. with the 0- antagonist naltrindole (10 mg kg-I, 15 min) or the K-
antagonist nor-BNI (32 mg kg-I, 24 hr) had no effect on the antinociceptive effect of 
BUn. In contrast, pre-treatment i.p. with the long-lasting 11- antagonist M-CAM (1.8 
mg kg-I, I hr) [Broadbear et aI., submitted for publication] fully inhibited the 
antinociception produced by Bun. The doses of antagonists used have been shown 
in our laboratory to be selective for the respective opioid receptor subtype (J. 
Broadbear, unpublished observations, see Table 4.3). In addition, administration of 
BU72 induced behavioural phenomena typically associated with l1-opioid agonists, 
inducing a Straub tail and an increase in locomotor activity [Aceta et al., 1969; Rethy 
et al., 1971]. Diuresis and sedation, behavioral effects associated with K-agonist 
action [Leander et aI., 1987], were observed after administration of a high dose (10 
mg kg-I) of BUn. These K-agonist effects were blocked by pre-treatment with nor-
BNI (32 mg kg-I). 
EDso (mg kg· l ) 
Antagonist Morphine Bremazocine BW373U86 
None 0.55 (0040-0.77) 0.012 (0.01-0.015) 2.81 (1.60-4.93) 
M-CAM 40.8 (19.5-85.8) 0.009 (0.006-0.014) 5.58 (4.18-8.18) 
1.8 mg kg· l , 1 hr 
Table 43 Potencies of morphine (11), bremazocine (l() and BW373U86 (I» in the 
mouse acetic acid-induced writhing assay and their antagonism by M-CAM. Values 
in parentheses represent the 95 % confidence limits. Data from Broadbear et ai., 
submitted for publication. 
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Figure 4.6 Antinociceptive effects of cumulative doses of BUn before and after pre-
treatment with the selective opioid antagonists M-CAM, 1.8 mg kg· l , 1 hr, 
naltrindole, 10 mg kg· l , 15 min; and nor-BNI, 32 mg kg' I , 24 hr in the 
warm water tail withdrawal assay. Values represent the mean ± S.E.M for 
5 mice. 
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2. Agonist actions - Time course of antinociception 
The antinociceptive time course of BUn relative to morphine and buprenorphine was 
determined in the tail withdrawal assay administered i.p. and writhing assay 
administered s.c. (Figs. 4.7 and 4.8). The doses of drug chosen were those which 
produced maximum anti nociceptive effect in each assay system. In the tail 
withdrawal assay BUn (0.32 mg kg") still retained some antinociceptive activity at 
12 hr as compared to morphine (lOO mg kg") which had a duration of action of less 
than 5 hr. The anti nociceptive effect of buprenorphine (3.2 mg kg") lasted 
approximately 8 hr. A higher dose of BUn (10 mg kg") maintained antinociception 
for up to 24 hr, and in the writhing assay lasted for up to 48 hr. 
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Figure 4.7 Time-course of the antinociceptive effects of bolus doses of morphine, 
buprenorphine, and BUn in the warm water tail withdrawal assay. 
Values represent mean ± S.E.M for 5 mice. 
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Figure 4.8 Time·course of anti nociceptive effects of a bolus dose of morphine and 
BUn in the writhing assay. Control writhing = 12.2 ± 2.5 writhes. 
Values shown are mean ± S.E.M for 5 mice. 
3. Agonist actions - Reversibility 
Due to the inability of naloxone to reverse the effects of buprenorphine once 
established [e.g. France et al., 1994], it was thought that perhaps the long·lasting 
antinociception produced by BUn may be a result of a tight interaction with the 
receptor, similar to buprenorphine. The ability of naloxone and naltrexone to reverse 
the antinociceptive effect of BUn was investigated in the tail withdrawal assay (Fig. 
4.9). Although naloxone and naltrexone (10 mg kg-I) were unable to reverse the 
anti nociceptive effect of a high dose of BUn (10 mg kg-I) administered 1 hr 
previously, both antagonists were able to fully reverse the antinociceptive effect of 
BUn at a dose of 0.32 mg kg-I. However BUn attenuated antinociception once the 
naloxone was no longer effective. This was approximately 2 - 3 hr after 
60 
administration of the antagonist. Naltrexone was longer lasting than naloxone and 
blocked the antinociceptive effect of BUn for at least 7 hr. 
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Figure 4.9 Reversal of the anti nociceptive effect produced by BUn (0.32 mg kg·1 or 
10 mg kg· l ) using either naloxone or naltrexone, both 10 mg kg·1 i.p., in 
the tail withdrawal assay. Values represent mean ± S.E.M for 5 mice. 
NX = naloxone, NTX = naltrexone. 
Naloxone and naltrexone were unable to reverse the observed analgesia produced 
by a large dose (10 mg kg· l ) of BUn (Fig. 4.9). It was noted however that both 
antagonists appeared to block the sedation produced by this dose of BUn. To 
quantify this effect the locomotor activity of the mice was examined by counting the 
number of times the mouse crossed a light beam either in the horizontal or vertical 
plane (Fig. 4.10). After a habituation period during which time a sterile water 
injection was administered, mice were injected i.p. with BU72. A complete decrease 
in locomotor activity counts was observed as the mice became sedated. The mean 
total locomotor count 20 min after a sterile water injection was 78, this decreased to 
13 counts after administration of Bun. One hr later, naloxone (10 mg kg-I, i.p.) was 
given. Approximately 15 min after the naloxone injection a normal level of 
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locomotor activity was observed with the mean count returning to 93. Sedation was 
seen to occur at 2 hr when naloxone was no longer effective. 
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Figure 4.10 Measurement of total locomotor activity counts before and after 
administration of BUn, 10 mg kg"! and reversal by naloxone, 10 mg 
kg·!. Each point represents the mean count of 8 mice. 
4. Antagonist actions 
Kamei et al., [1996] have shown that the highly efficacious opioid, dihydroetorphine 
(DHE), is able to block the effects of subsequently administered morphine in mice. 
Since BUn is also highly efficacious and longer lasting than DHE, it was of interest 
to determine if the antinociceptive effect of morphine was blocked following BU72 
administration, particularly since the aim of this study was to evaluate the potential of 
BUn as a treatment drug. The dose-response curve for morphine in the tail 
withdrawal assay was determined before and after pre-treatment with BUn (0.32 or 
10 mg kg·!). When the antinociceptive effect of a 0.32 rng kg·! i.p. dose of Bun had 
fully diminished (18 hr) a 3-fold shift in the dose-response curve to morphine was 
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observed from a control ED50 of 27.1 mg kg" (95 % Cl = 18.0 - 40.9 mg kg''), to an 
ED50 at 18 hr of 72.4 mg kg" (95 % Cl = 41.8 - 125.4 rng kg" ) (Fig. 4.11). A similar 
shift in the morphine dose-response curve was observed 24 hr after pre-treatment but 
due to a larger 95 % confidence interval the ED50 was found to be not statistically 
significantly different from the ED50 for morphine control. No significant shift was 
observed after pre-treatment for 48 or 72 hr. A higher dose of BU72 (10 mg kg-', i.p.) 
produced antinociception for 28 hr, after which time the dose-response curve of 
morphine was observed to give an ED50 of 58.8 mg kg-' (95'% Cl = 39.5 - 87.5 mg 
kg"') (Fig. 4.12). After a pre-treatment time of 72 hr this shift increased to 7-fold 
greater than control, giving an ED50 of 188 mg kg-I. Due to fatalities at higher doses 
of morphine the upper limit of the 95 % Cl could not be calculated. A week after 
single dose pre-treatment the ED50 for morphine (24.5 rng kg" (95 % Cl = 10.92 -
54.98 mg kg-I) had returned to control value. Administration of a single s.c. dose of 
BU72 (10 mg kg-I) produced a larger shift (ED50 = 468 rng kg" after 72 hr) than the 
equivalent i.p. dose. 
An acute dose of BU72 (0.32 mg kg"') did not cause a shift in the dose-response 
curve of BU72. The ED50 for BU72 in naive animals was 0.07 mg kg-', (95 % Cl = 
0.05 - 0.09 mg kg-I) and 18 hr after BU72 administration the ED50 remained the same 
(0.07 mg kg-I, 95 % Cl = 0.04 - 0.12 mg kg-I). In contrast to BU72, 5 hr after 
administration of a maximal dose of methadone (32 rng kg''), at which time 
methadone was no longer effective, the degree of antinociception produced by 
morphine was unchanged from control mice, ED50 = 24.0 rng kg-' (95 % Cl = 11.3 -
51.0 mg kg-I). 
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Figure 4.11 Antinociceptive effect of morphine before and after pre-treatment with 
BUn (0.32 mg kg·') for 18 hr, 24 hr, 48 hr, and n hr in the tail 
withdrawal assay. Values represent mean ± S.E.M for 5 mice. 
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Figure 4.12 Antinociceptive effect of morphine before and after pre-treatment with 
BUn (10 mg kg·') for 28 hr, 48 hr, n hr and 1 week in the tail 
withdrawal assay. Values represent mean ± S.E.M for 5 mice. 
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The antagonist effect of BUn was also detennined in the writhing assay. In naive 
animals morphine (3.2 mg kg· l ) completely blocked writhing but 24 hr after a pre-
treatment with a low dose of BUn (0.32 mg kg· l ) the antinociceptive effect of 
morphine was partially blocked; returning to 25 % of control, and 86 % of control 
after 12 hr. The antinociceptive effect of morphine returned to normal after I week (2 
% of control) (Fig. 4.13). After a 12 hr pre-treatment with a high dose'of BUn (10 
mg kg· l ) the antinociceptive effect of morphine was antagonized to 73 % of control. 
This value was not significantly different from control. Morphine was still ineffective 
after I week (86 % of control, not significantly different from control) and even after 
14 days the antinociception produced by morphine was still partially blocked (24 % of 
control) (Fig. 4.14). 
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Figure 4.13 Antinociceptive effect of morphine (3.2 mg kg· l ) in the writhing assay 
before and after pre-treatment with BUn (0.32 mg kg· l ) for 24 hr, 48 hr, 
12 hr, and I week. Control writhing = 14.0± 1.9 writhes. Values 
represent mean ± S.E.M for 6 mice. ** P< 0.01, * P< 0.05 vs morphine 
alone, Students' unpaired t-test. 
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Figure 4.14 Antinociceptive effect of morphine (3.2 mg kg· l ) in the writhing assay 
before and after pre-treatment with BUn (10 mg kg· l ) for 24 hr, 48 hr, 
n hr, I week and 2 weeks. Control writhing = 14.8 ± 1.9 writhes. 
Values represent mean ± S.E.M for 6 mice. *** P< 0.005, ** P< 0.01, 
vs morphine alone. Students' unpaired Hest. 
The effect of BUn pre-treatment on the antinociception produced by the o..agonist 
BW373U86 and the K-agonist bremazocine was also examined (Fig. 4.15). Seventy-
two hr after pre-treatment with a single 10 mg kg·1 S.C. dose of BUn, when morphine 
action is maximally blocked, the anti nociceptive effect of a maximally effective dose 
of BW373U86 (10 mg kg· l ) was reduced giving 39 % of control writhing. The 
antinociception produced by a maximally effective dose of bremazocine (0.1 mg kg· l ) 
was unaffected. 
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Figure 4.15 Antinociceptive effect of morphine (0.32 mg kg-I), BW373U86 (10 mg 
kg-'), and bremazocine (0.1 mg kg-'), before and after pre-treatment with 
BUn (10 mg kg-'). Control writhing = 10.7 ± 2.4 writhes. Values 
represent mean ± S.E.M for 6 mice. ** P< 0.01 vs agonist alone, 
Students' unpaired t-test. 
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4.3 Discussion 
The present study indicates that the morphinan-pyrrolidine BUn is a highly 
efficacious l1-opioid receptor agonist with subsequent 11- antagonist properties, which 
are particularly striking in the writhing assay. Similar to buprenorphine, BUn binds 
with high affinity to the l1-opioid receptor, but is relatively non-selective in agreement 
with previous data obtained in guinea-pig brain membranes [Husbands & Lewis, 
1995]. It is interesting to note that the Ki value for the binding of BUn to 
membranes from C6 cells expressing the cloned l1-receptor was lower than the Ki for 
the binding of BUn to the l1-receptor in mouse brain membranes. This may reflect 
differences in the competing tritiated ligand, as eHlDAMGO was used in competition 
assays using mouse brain membranes and eH]diprenorphine was used for competition 
binding using C611 cells. Results from our laboratory suggest that these two ligands 
have different binding requirements [Lee et al., submitted for publication]. In C611 
cells BUn was a more efficacious agonist than fentanyl, 600 times more potent than 
morphine and approximately 40 times more potent than buprenorphine which, as 
expected, was only a partial agonist. 
In accordance with its high in vitro l1-efficacy BUn produced dose-dependent 
antinociception in both the tail withdrawal and writhing assays. On administration of 
0.1 mg kg-' and above behavioral effects typically associated with l1-opioid receptor 
ligands were observed [Aceto et aI., 1979; Rethy et al., 1971], such as an increase in 
locomotor activity and Straub tail. Confirmation that the antinociception was 
mediated through the l1-opioid receptor was obtained by inhibition of the 
anti nociceptive response by pre-treatment with the irreversible l1-selective antagonist 
M-CAM. Neither the o-selective antagonist naltrindole, nor the K-selective antagonist 
nor-BNI had any effect on the antinociception produced by Bun. Diuresis and 
sedation; behavioral effects associated with 1(-agonist action [Leander et aI., 1987], 
were observed after administration of a high dose (10 mg kg-I) of BUn and blocked 
by pretreatment with nor-BNI (32 mg kg-'). This is consistent with the high affinity 
of the compound for the 1(-receptor, but the higher doses required to observe this 
effect agree with the preferential activity of the compound at 11-, rather than 1(-
receptors, in the tail withdrawal assay. 
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It is interesting to note that in one experiment a dose of 32 mg kg·', that is 100 
times the dose needed to produce antinociception in the tail withdrawal assay, was 
administered safely. This is in contrast to our findings with morphine and methadone, 
where a dose 10 times that needed to produce maximum antinociception is lethal in 
the NIH strain of mice used in this study. 
An important feature of a treatment drug is a long duration of action, this being one 
of the characteristics of buprenorphine that makes it particularly attractive alternative 
to methadone. BUn has a duration of action longer than both morphine and 
buprenorphine. It is thought that buprenorphine is long-lasting because the C7 t-butyl 
group forms a tight lipophilic interaction with the receptor, thus slowing down its 
dissociation kinetics [Hambrook and Rance, 19761. It is difficult to reverse the 
agonist action of buprenorphine once it is established [Cowan et al., 1977a, France et 
al., 19841, so it was of interest to determine if the reason for the long duration of 
action of BUn was due to irreversible or pseudo-irreversible binding to the ~-opioid 
receptor. However, the antinociceptive effect of Bun (032 mg kg·') was completely 
reversed by both naloxone and naltrexone. Furthermore BUn still had access to ~­
receptors several hr after administration as antinociception was once more observed 
when the effect of naloxone had dissipated. Although the antinociception produced 
by a high dose of BUn (10 mg kg·') could only be partially reversed by naloxone, the 
level of sedation, as measured by locomotor activity, was fully reversible. These data 
would suggest that the mechanism behind the long duration of action is different from 
that of buprenorphine, and probably involves the continued presence of BUn in the 
central tissue rather than a persistent binding to the ~-opioid receptor. 
The ability to block the effects of subsequently administered opioids is also an . 
important pharmacological characteristic of a treatment drug. The antagonist action 
of BUn was therefore studied in both the tail withdrawal and writhing assays. Once 
an anti nociceptive effect of BUn was no longer apparent a shift in the dose-response 
curve of subsequently administered morphine in the tail withdrawal assay was 
observed. This antagonism appeared to develop over time, and was more pronounced 
in the writhing assay. In the tail withdrawal assay, the greatest shift was seen at 18 -
24 hr in the case of 032 mg kg"' BUn and at 48 - n hr in the case of 10 mg kg·' 
BUn. In the writhing assay a maximal dose of morphine was partially suppressed 
for up to 3 days after pre-treatment with a single dose of 032 mg kg·' BUn. Using a 
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higher dose of BUn (10 mg kg-I) the antinociceptive action of morphine was 
completely suppressed 3 days after a single dose and still not fully effective after two 
weeks. At this dose of BUn an antagonist effect against the 8-agonist BW373U86 
was observed but the antinociceptive effect of the x-agonist bremazocine was 
unaffected. However it is known that BW373U86 does have a Il-agonist component 
[A. Alt, our laboratory, personal communication], which would be susceptible to 
antagonism by BUn. The ability of BUn to produce full antagonism of morphine 
for several days is comparable to the effects seen with irreversible Il-antagonists such 
as clocinnamox (C-CAM) [Zemig et al., 1995]. 
Initially it was thought that BUn was binding to the J.I.-receptor in an irreversible 
manner similar to buprenorphine, hence the long-duration of action. However, the 
data has shown that BUn is reversible by antagonist administration in both 
antinociception and locomotor assays. It is possible that BUn is causing down-
regulation of the Il-receptor, leading to reduced effectiveness of subsequently 
administered Il-agonists. In vivo regulation of J.I.-opioid receptors by agonists has 
yielded variable results, some reporting up-regulation and some reporting down-
regulation [Tempel et al., 1988; Brady et aI., 1989, Yobum et aI., 1993], but it has 
been shown that chronic treatment for longer periods of time with high (usually toxic) 
doses of high efficacy agonists such as etorphine and fentanyl can produce down-
regulation of opioid receptors [Tao et al., 1987, Yobum et al., 1993]. We would 
perhaps, therefore, not expect a single dose of BU72 to produce down-regulation of 
the Il-opioid receptor. Another possibility is desensitization without down-regulation, 
although it has also been shown that acute treatment with etorphine does not affect 
either receptor density or affinity of the agonist for the receptor [Yobum et al., 1993; 
Tao et aI., 1987]. In spite of this the most likely explanation for delayed antagonist 
action of BUn is the production of tolerance to morphine. This also allows an 
explanation as to why pretreatment with BUn does not prevent the subsequent 
agonist action of BUn, i.e. tolerance to BUn is not evident as the highly efficacious 
nature of the compound means only a few receptors need to be activated to evoke a 
full anti nociceptive response. 
These results are similar to data obtained with dihydroetorphine (DHE) , an 
oripavine-thebaine derivative 12000 times more potent than morphine [Bentley & 
Hardy, 1967]. It has been reported that DHE possesses antagonist properties at the J.I.-
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opioid receptor [Kamei et aI., 1996]. OHE, despite its high efficacy, apparently has 
low physical dependence capacity and has been successfully used to detoxify more 
than 3000 opiate addicts in China [Wang et aI., 1992]. Using the radiant heat tail-
flick assay in mice, Kamei et af. showed that an i.p. injection of 10 ~g kg·1 ORE 
produced an anti nociceptive effect for up to 90 min after administration. After this 
time the antinociceptive effect of subsequently administered morphine was 
significantly reduced for up to 6 hr. A similar antagonism of morphine was seen 
using buprenorphine instead of OHE. The authors concluded that either acute 
tolerance to ~-opioid receptor agonist-induced antinociception was occurring, or that 
ORE and buprenorphine were interacting with a separate 'antagonist' recognition site 
which is allosterically coupled to the ~-receptor 'agonist' binding site [Portoghese & 
Takemori, 1983]. The results obtained with ORE and buprenorphine are similar to 
the present finding obtained with BUn, suggesting that a common mechanism of 
action may be responsible for the favourable profile of these compounds as potential 
treatment drugs. 
If tolerance development at the ~-opioid receptor by BU72 is the reason for loss of 
efficacy of morphine, then the question arises as to why BUn is more effective at 
antagonizing morphine in the writhing than the tail-withdrawal assay; when based on 
receptor theory [Kenakin, 1997] we would expect to see greater antagonism at the 
system requiring higher efficacy i.e. the tail withdrawal assay. One possibility is that 
different ~-receptor populations are involved. This would explain why BUn has 
similar potency in the tail-withdrawal and writhing assays when morphine 
differentiates the two assays, and is 50-times more potent in the latter assay. However, 
a simpler explanation may relate to the pharmacokinetics of BUn, following the 
different injection routes employed in the tail-withdrawal assay (i.p.) and the writhing 
assay (s.c.) leading to a greater tolerance following s.c. administration. In support of 
this, the antagonist action of BUn was greater following s.c. than i.p. administration 
in the tail withdrawal assay. 
In conclusion BUn is a highly efficacious ~-opioid receptor agonist with 
subsequent properties that inhibit the antinociceptive action of morphine for up to one 
week in mice. If this transfers to man this would provide efficacy for patient 
compliance, followed by blockade of the reinforcing effects of any subsequently 
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administered opiate. Experiments in non-human primates are in progress to answer 
this question. 
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CHAPTERS 
CHARACTERISATION OF 3-ALKYL ETHER DERIVATIVES OF 
METHOCLOCINNAMOX 
5.1 Introduction 
The 14-cinnarnoylamino codeinone, methoclocinnarnox, (MC-CAM; BU28, Fig.5.1), 
has aroused interest in recent years due to its potential as a therapeutic agent for the 
treatment of opioid abuse [Woods et aI., 1995]. MC-CAM is a member of an unusual 
series of compounds comprising the long-lasting 'pseudoirreversible' antagonist 
clocinnarnox (C-CAM; BU\8, Fig. 5.1) [Aceto et aI., 1989, Corner et al., 1992] and 
other similarly 14-substituted cinnamoylamino morphinones and codeinones [e.g. 
liang et al., 1993]. These compounds are relatively selective for the ~-receptor but 
display varying degrees of efficacy [Lewis et al., 1988]. MC-CAM itself exhibits 
initial partial agonist activity followed by long-lasting antagonism at the ~-receptor in 
a number of in vivo assays including the warm water tail withdrawal assay in rhesus 
monkeys [Butelman et aI., 1996], and the mouse writhing assay and tail withdrawal 
assay [Aceto et al., 1989]. This may be due to metabolism of MC-CAM to its 
corresponding morphinone, C-CAM [Woods et al., 1995]. Indeed in our hands MC-
CAM also exhibits a bell-shaped dose-response curve similar to that observed with 
buprenorphine in the rat tail withdrawal assay [our laboratory, unpublished 
observations, see also Husbands et aI., 1998]. Taken together these features suggest a 
common mechanism of action which may be important as a potential treatment drug. 
More recently this series of compounds has been extended to include ethers of C-
CAM, other than the methyl ether MC-CAM, in which the 3-0H is replaced with 
larger alkyl groups. These compounds .have been investigated for their efficacy and 
long-lasting antagonism in vitro and in vivo [Husbands et al., 1998]. In rat brain 
homogenates all compounds bound with high affinity to the ~-opioid receptor, despite 
the presence of the 3-alkyl substituents. In the mouse warm water tail withdrawal 
assay several of the compounds displayed a higher degree of efficacy than MC-CAM, 
with the exception of the cyclopropylmethyl ether which showed no agonist activity, 
but a profile similar to that of C-CAM. As observed with MC-CAM, those ethers 
showing agonist activity also displayed delayed, long-lasting, ~-antagonist activity. 
In order to further characterize these compounds and to understand this unique 
mechanism of action similar to what has been previously observed with BUn in 
Chapter 4, the binding profile of the ethers and the in vitro efficacy using the 
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eSS]GTPyS assay has been examined using membranes prepared from SH-SY5Y 
human neuroblastoma cells. 
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BUl8 (C-CAM) R=H 
BUl9 R = CHr CH=CH2 
BU20 R=CHrC=N 
BU21 R=CPM 
BU22 R = CH2CH2CH3 
BU23 R=CH2C=CH 
BU24 R = CH2C02CH3 
BU25 R=CH(CH3h 
BU28 (MC-CAM) R=CH3 
Figure 5.1 The structures of the 3-substituted 14-cinnamoylamino compounds. 
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5.2 Results 
5.2.1 Radioligand Binding Assays 
C-CAM (BUI8) and its 3-alkyl ethers (BU19 - 25, 28) (Fig. 5.1) showed high affinity 
for the IJ.-receptor in membranes prepared from SH-SY5Y human neuroblastoma cells 
(Figs. 5.2 - 5.6). All of the ethers, with the exception of the isopropyl ether BU25, 
displayed a biphasic displacement curve for the inhibition of eHlDAMGO binding to 
SH-SY5Y cell membranes giving Hill coefficients (Table 5.1) of less than unity 
except for that obtained for BU25, which was closest to unity at 0.77. Displacement 
curves were subsequently analyzed using GraphPad Prism and a best fit to a two-site 
binding model was confirmed (all P values < 0.0005) for all the compounds with the 
exception of BU25. The fraction of binding to the high affinity site varied from 32 % 
for the cyclopropylmethyl ether BU21 to 69 % for the propargyl ether BU23. The 
irreversible IJ.-ligand J3-funaltrexamine (J3-FNA) showed high affinity binding that was 
monophasic. 
The rank order of affinity of the 3-alkyl ethers as determined by radioligand 
binding is as follows: For site I (high affinity site): C-CAM > propargyJ (BU23) > 
nitrile (BU20) > allyl (BUI9) > methyl (MC-CAM) > cyclopropylmethyJ (CPM) 
(BU21) > n propyl (BU22) > ester (BU24). For site 2 (low affinity site) : C-CAM > 
methyl> isopropyl> allyl> nitrile> ester> CPM > propargyl > n propyl. 
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Figure 5.2 The displacement of eH]DAMGO by C-CAM (BU18) and MC-CAM 
(BU28) in SH-SY5Y cell membranes. Values for this and each 
subsequent graph represent means ± S.E.M for at least three experiments 
performed in duplicate. SB = specific binding. 
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Figure 5.3 The displacement of eHlDAMGO by BU19 and BU20 in SH-SY5Y cell 
membranes. 
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Figure 5.4 The displacement of eH]DAMGO by BU2l and BU22 in SH-SY5Y cell 
membranes. 
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Figure 5.5 The displacement of eH]DAMGO by BU23 and BU24 in SH-SY5Y cell 
membranes. 
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Figure 5.6 The displacement of eH]DAMGO by BU25 in SH-SY5Y cell membranes. 
Hill Ki 1 Ki 2 Fraction Fraction 
Coefficient Site 1 Site 2 
BUJ8(C-CAM) 0.41 ± 0.03 0.004 ± 0.001 1.2 ± 0.2 0.47 0.53 
BUJ9 0.50 ± 0.Q2 0.068 ± 0.013 10.1 ± 0.6 0.48 0.52 
BU20 0.39 ± 0.03 0.036±0.015 11.6± 3.5 0.53 0.47 
BU21 0.58 ±0.08 0.096 ± 0.025 13.8± 1.5 0.32 0.68 
BU22 0.50 ± 0.04 0.121 ± 0.026 23.8 ± 8.6 0.41 0.59 
BU23 0.34 ± 0.03 0.009 ± 0.002 16.2 ± 7.6 0.69 0.31 
BU24 0.52 ± 0.07 0.121 ± 0.040 12.4 ± 2.6 0.57 0.43 
BU25 0.77 ±0.1O N/A 9.3 ± 1.2 N/A 1.0 
BU28 0.63 ±0.05 0.094 ± 0.024 3.50±0.6 0.56 0.44 
(MC-CAM) 
Table 5.1 Ki values and Hill coefficients for the displacement of eH]DAMGO by 
BU compounds in SH-SY5Y cell membranes. Values represent means ± 
S.E.M for at least three expenments performed in duplicate. NI A = not 
applicable, single site competition. 
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In order to detennine if the biphasic nature of the displacement curves obtained 
was particular to l1-receptors in the SH-SY5Y cell line, the displacement of the 
selective 11-ligand eHlDAMGO by C-CAM, the cyc\opropylmethyl ether, BU21, and 
the isopropyl ether, BU25, was investigated in guinea-pig brain membranes (Figs. 5.7 
and 5.8). Again a biphasic displacement curve for C-CAM was found, whereas the 
curves for BU21 and BU25 were best fit to a one-site model. The affinities of these 
ligands for the l1-receptor sites in guinea-pig brain homogenate were similar to the 
affinities for the low affinity site obtained in SH-SY5Y cell membranes. K j values for 
the displacement of eHlDAMGO in guinea-pig brain membranes by C-CAM, BU21, 
and BU25 are given in Table 5.2. However, the fraction of C-CAM binding to the 
receptor population in the higher affinity site is considerably lower in guinea-pig 
membranes (16 %) as compared to SH-SY5Y cell membranes (47 %) (Table 5.2). 
In membranes prepared from C6 glioma cells expressing only the l1-opioid 
receptor, C-CAM also showed biphasic displacement with approximately 46 % of the 
binding to the higher affinity site (Fig. 5.9). Since guinea-pig brain homogenates 
contain 11-, 0-, and K-receptor subtypes, and the SH-SY5Y cell line contains 11- and 0-
receptors, the use of the C6 cell line expressing only the l1-receptor eliminated the 
possibility of an interaction with another opioid receptor type. 
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Figure 5.7 The displacement of eH]DAMGO by C-CAM and BU25 in guinea-pig 
brain membranes. 
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K; I (nM) K; 2 (nM) Fraction site I Fraction site 2 
BUlB 0.0125 ± 0.009 2.6 ± 0.4 0.16 0.B4 
BU21 N/A 15.0 ± 1.3 N/A 1.0 
BU25 N/A 9.3 ± 1.9 N/A 1.0 
Table 5.2 K; values for the displacement of eH]DAMGO by C-CAM (BUlB), BU21 
and BU25 in guinea-pig brain membranes. 
NI A = not applicable, single site competition. 
In order to determine if the biphasic curves were a result of a single binding site 
existing in multiple affinity states, for example, coupled and uncoupled forms of the 
receptor, the binding was determined in the presence of NaCl and the GTP analogue 
GppNHp. This serves to uncouple the G-protein resulting in only a low affinity state 
of the receptor. To test this the displacement of eH]diprenorphine by C-CAM was 
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investigated in membranes prepared from C6 glioma cells (Fig. 5.9). Diprenorphine 
is an antagonist at the !1-receptor and possesses equal affinity for both high and low 
affinity sites. Under both conditions C-CAM still recognized two components of 
binding, and there was no difference in Ki values in the presence or absence of Na+ 
ions confirming the antagonist action of C-CAM. 
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Figure 5.9 The displacement of eH]diprenorphine by C-CAM in membranes 
prepared from C6 cells expressing the cloned !1-opioid receptor, with 
and without the presence of NaCI and the GTP analogue, GppNHp 
present in the binding buffer. 
A time-course of the displacement of eH]DAMGO in SH-SY5Y cell membranes 
was undertaken to determine' if the biphasic nature of the curves varied with 
incubation time. For this study C-CAM was used and compared to BU25 (Fig. 5.10). 
Membranes were incubated with drug and radioligand for 1, 2, and 3 hr. Variation of 
incubation time did not affect the displacement curve of BU25, however a flattening 
of the displacement curve was observed with time for C-CAM. After a 3 hr 
incubation period C-CAM at a concentration of 3 pM was able to displace 61 % of 
specific eH]DAMGO binding, compared with 14 % after I hr. The Ki values for the 
displacement of eH]DAMGO by C-CAM from the higher affinity site increased with 
time, changing from 4.1 ± 1.0 pM after a 1 hr incubation to 0.52 ± 0.09 pM after a 3 
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hr incubation. The fraction of binding to the higher affinity site also increased with 
time, changing from 47 % to 74 % and 78 % for 2 hr and 3 hr incubation times 
respectively. 
100 
0 
" 
80 
:i~ C'2 
~,-
60 
J:IU 
C') E 
~CII 40 !Da: (J) 
"# 20 
0 
-12 -11 
... 
-10 -9 -8 
log[Drug] (M) 
-7 
• C-CAM 60 mins 
o BU25 60 mins 
• C-CAM 120 mins 
o BU25 120 mins 
... C-CAM 180 mins 
v BU25 180 mins 
·6 
Figure 5.10 The displacement of eH]DAMGO by C-CAM and 8U25 in SH-SY5Y 
cell membranes after different periods of incubation. 
A number of studies have shown that changes in membrane microviscosity result 
in profound effects on opioid receptor binding [Creese et al., 1975, Remmers & 
Medzihradsky, 1991, Zhang & Yang, 1989]. The displacement of eH]diprenorphine 
by C-CAM and 8U25 in C61l cell membranes was carried out at 37°C for an 
incubation time of 1 hr, and at 4°C for an incubation time of 4 hr (Fig. 5.11), in order 
to promote or hinder access to receptor binding sites by increasing or decreasing 
membrane fluidity. It should also be noted that an increase or decrease in incubation 
temperature can simply speed up, or slow down, the attainment of equilibrium in 
binding. Neither temperature change affected the nature of the displacement curve for 
C-CAM, although incubation at 37°C increased the fraction of the binding to the 
higher affinity site to 87 %, from 46 % at 25°C for 1 hr, and also significantly 
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increased the affinity for this site ten-fold (K; = 0.4 ± 0.1 pM, P = 0.02, Students' 
unpaired t-test). There was no change in fraction of binding to the higher affinity site 
after incubation at 4°C (45 %), nor was there a significant change in affinity (K; = 4.8 
± 4.4 pM). The binding of the isopropyl ether 8U25 was unaffected by changes in 
incubation temperature (data not shown). 
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Figure 5.11 The displacement of eH]diprenorphine by C-CAM in C6j.! cell 
membranes. Incubation temperatures of 4°C for 4 hr and 25°C or 37°C 
for 1 hr were used. 
It has been shown previously that a j.!-opioid receptor population is resistant to 
alkylation by the irreversible ligand ~-funaltrexamine (~-FNA) (Elliott et al., 1994). 
Fig. 5.12 shows the results from a wash-resistance study, where pre-treatment of C6j.! 
cells with lOO nM I3-FNA resulted in a partial knock-out of receptor number. The 
percentage of receptors still able to bind eH]DAMGO following I3-FNA treatment 
was 42.6 ± 8.0 %, confirming the results of Elliott et al. To examine the possibility 
that the I3-FNA-resistant population was related to one of the sites recognized by C-
CAM and its 3-alkyl ethers, binding studies using C-CAM were carried out in C6j.! 
cells which had been pre-treated with this maximal dose (100 nM) of I3-FNA (Fig. 
84 
5.13). C-CAM once again exhibited a biphasic displacement curve indicating that the 
~-FNA-resistant population is not identical to one of the sites recognized by C-CAM. 
1 
0 
" ~~ C .- 60 
....... 5 M:' ~ 
m Q) ... 40 
U) 
~ 0 20 
0 Control b-FNA-treated 
Figure 5.12 Wash-resistant binding of ~-FNA to the Il-receptor in C6 glioma cells, as 
determined by a reduction in specific binding of [3H]DAMGO. Cells 
were incubated for I hr at 37°C with vehicle control or drug and then 
washed 5 times prior to membrane preparation. Values represent mean 
± S.E.M for four experiments carried out in duplicate. 
Figure 5.13 The displacement of eH]DAMGO by C-CAM in C61l cell membranes 
before and after treatment of the cells with 100 nM ~-FNA. 
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C-CAM is a long-lasting 'pseudoirreversible' antagonist for the l1-opioid receptor, 
as is MC-CAM. The unusual binding profile of these compounds may therefore relate 
to their ability to form tight hydrophobic interactions with the l1-receptor over time. If 
this is indeed the case, then one might expect 8U25 to be a fully reversible since it 
does not show the same binding pattern as the other compounds in this series. The 
ability of BU25 to bind in a wash-resistant manner to the l1-opioid receptor expressed 
in C6 glioma cells was examined and compared to C-CAM and MC-CAM (Fig. 5.14). 
Cells were incubated for I hr with drug and subsequently washed 5 times to remove 
any unbound drug prior to membrane preparation. As can be seen pre-treatment of 
cells with 100 nM C-CAM and MC-CAM resulted in a complete block of 
eH]DAMGO binding. In contrast, 8U25 pre-treatment, up to a concentration of 100 
nM, did not affect the binding of eH]DAMGO to the l1-receptor. 
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Figure 5.14 Wash resistant binding of C-CAM, MC-CAM and BU25 to C611 cells, as 
determined by reduction in specific eH]DAMGO binding to cell 
membranes. Cells were incubated for 1 hr at 37°C with either vehicle 
control or drug and then were washed 5 times before membrane 
preparation. 
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5.2.2 r35S]GTP;5 binding assays 
The 3-alkyl ethers were tested up to a concentration of 1 !lM in the e5S]GTPyS assay. 
The compounds varied in efficacy ranging from antagonist, (C-CAM and the 
isopropyl ether 8U25), to partial agonist, giving up to 50 % of the fentanyl response 
(Figs. 5.15 - 5.19). EC50's and maximal stimulation relative to that produced by 10 
!lM fentanyl are given in Table 5.3. The rank order of potency of the ethers as 
obtained from the e5S]GTPyS assay was as follows: methyl (8U28, MC-CAM) > 
allyl (8U19) > propargyl (8U23) > nitrile (8U20)>> ester (8U24) > n propyl 
(BU22) > CPM (BU21). 
EC50 (nM) % Maximal Stimulation 
(relative to fentanyl) 
BU18 (C-CAM) N/A 0 
BU19 0.10 ± 0.03 nM 50.6±4.2 
BU20 5.93 ± 1.98 15.7 ± 6.3 
BU21 158.0 ± 58.1 32.8 ± 1.2 
BU22 111.4 ± 80.7 41.0±7.0 
8U23 1.18 ± 0.87 32.2 ±4.4 
BU24 72.7 ±68.8 13.8 ± 2.8 
BU25 N/A 0 
BU28 (MC-CAM) 0.03 ±0.02 21.9 ± 3.4 
DAMGO 10.2* 97.0* 
Table 5.3 EC50 and % maximum stimulation values for the stimulation of e5S]GTPyS 
binding by the BU compounds. Values represent mean ± S.E.M. of at 
least three experiments perfonned in duplicate. * = mean of one 
experiment perfonned in duplicate. NI A = not applicable, zero 
stimulation measured. 
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Figure 5.15 Stimulation of e5S]GTPyS binding by C-CAM in SH-SY5Y cell 
membranes relative to the full IL-agonist fentanyl. Values for this and 
subsequent figures represent the mean ± S .E.M for at least three 
experiments performed in duplicate. 
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Figure 5.16 Stimulation of e5S]GTPyS binding by BU19 and BU20 in SH-SY5Y cell 
membranes. 
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Figure 5.17 Stimulation of eSS]GTPyS binding by BU21 and BU22 in SH-SY5Y cell 
membranes. 
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Figure 5.18 Stimulation of eSS]GTPyS binding by BU23 and BU24 in membranes 
prepared from SH-SY5Y cells. 
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Figure 5.19 Stimulation of eSS]GTPyS binding by BU25 and BU28 (MC-CAM) in 
SH-SY5Y cell membranes. 
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5.3 Discussion 
The results clearly demonstrate that all of the tested 3-a1kyl ether 14-
cinnamoylamino compounds bind to the I.l-opioid receptor in cultured cells and in 
guinea-pig brain with high affinity. This correlates well with the data of Husbands et 
al., 1998, who reported on the binding affinities of the 3-alkyl ethers to rat brain 
membranes. However, with the exception of the iso-propyl ether, BU25, all of the 
compounds .in this series showed biphasic displacement of CHjDAMGO from 
membranes prepared from SH-SY5Y human neuroblastoma cells. C-CAM was also 
confirmed to show biphasic displacement in C61.l cell membranes. Husbands et al. 
did not report biphasic curves. Interestingly, in guinea-pig brain membranes the 
fraction of binding to the high affinity site was much lower than in SH-SY5Y and C6 
glioma cell membranes, suggesting that the degree of biphasic binding observed is 
dependent on the system used. It is possible that in brain homogenate the time of 
access to the receptor site is longer. Additionally, the displacement curve for BU21 
was monophasic in guinea-pig brain homogenates. This may explain why the 
previous studies of Husbands et al. did not uncover this biphasic binding in rat brain 
membranes. There are at least three possible explanations for the biphasic binding 
curves seen for these ligands: a) the compounds recognize a single site on the receptor 
existing in both high and low affinity states, b) the compounds are binding to two 
distinct sites of the I.l-opioid receptor or differentially to the same receptor site, or c) 
the compounds recognize different opioid receptors. Experiments in C6 glioma cells 
expressing only the I.l-opioid receptor enable us to eliminate the possibility of one of 
the sites being an interaction with another (0.. or 1(-) opioid receptor. 
To test the hypothesis that thebiphasic binding was a result of the ability of the 
drugs to distinguish between high and low affinity states of the receptor, competition 
binding assays were carried out using a C6 glioma cell line transfected with the 
cloned I.l-opioid receptor, in the presence of NaCl and the GTP analogue, GppNHp. 
Addition of N aCI and guanine nuc1eotides serves to uncouple the receptor from G-
protein hence promoting an inactive, low affinity state of the receptor and abolishing 
high affinity binding: Clearly from the results obtained the higher affinity binding 
component has been unaffected. Moreover, CHjdiprenorphine and C-CAM, the 
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ligands used in this assay, are both antagonists at the ~-receptor and so should 
recognize coupled and uncoupled states of the receptor with equal affinity. 
One feasible explanation is the presence of subtypes of the Il-receptor. This 
concept of multiple sUbtypes has been of interest to many researchers for several 
years. Evidence from binding [Wolozin & Pastemak, 1981, Nishimura et aI., 1984] 
and autoradiographic studies [Goodman & Pastemak, 1986] suggest that opiates and 
enkephalins bind to a common high affinity 'Ill' site, and that the opiates (but not the . 
enkephalins) also bind to a lower affinity '112' site. In vivo studies also support the 
presence of multiple subtypes of the Il-receptor. Naloxonazine and naloxazone, 
which irreversibly bind to the high affinity III site [Pastemak et al., 1980], have 
proved useful tools not only in binding experiments but in determining the specific 
pharmacological actions mediated by III and 112 sUbtypes in vivo [Ling & Pastemak, 
1983, Heyman et al., 1988]. It has been shown that rialoxonazine selectively 
antagonizes supraspinal morphine analgesia without affecting spinal morphine 
analgesia [Ling & Pastemak, 1983]. Additionally, naloxonazine does not antagonize 
the respiratory depressant actions of morphine [Ling et aI., 1985]. The authors ruled 
out the involvement of &'mechanism and concluded that respiratory depression was 
mediated via the 112 sub-population of receptors. Bare et al., 1994, reported that a 
splice variant of the human Il-receptor exists. This form of the receptor differs at the 
C-terminus and is eight amino-acids shorter than the originally established structure 
of the Il-receptor. Hollt and his colleagues also reported the on the cloning and 
expression of an isoform of the rat Il-receptor [Zimprich et al., 1995], and have shown 
more recently that the distribution of these isoforms of the Il-receptor is very 
different, suggesting· cell-specific receptor expression [Schulz et aI., 1998]. Splice 
variants therefore could represent Il-receptor sUbtypes. However it is unlikely that 
subtypes exist in the C6 glioma cell line transfected with a single cDN A. Therefore it 
would also seem unlikely that the 3-alkyl ethers are binding· to two distinct 
structurally different subtypes of the Il-receptor if biphasic curves are observed in 
membranes prepared from the C61l cell line. Caveat that Il-receptor sUbtypes could 
exist due to post -translational processing or coupling to different effector systems. 
If the biphasic binding curves do not arise as a result of a single binding site 
existing in multiple affinity states, and are probably not due to the existence of 
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multiple Il-receptor subypes, this leaves us with the possibility that the alkyl ethers 
have different Il-receptor binding modes. If this is the case, an important question is 
why the iso-propyl ether BU25 does not exhibit biphasic binding. This could be due 
to the fact that BU25 is a pure antagonist. However, this would also hold true for C-
CAM, yet C-CAM does exhibit biphasic binding. One possible explanation may be 
that one of the sites recognized by the other compounds in this series is a second site 
on the same receptor protein, probably that which is responsible for 
'pseudoirreversible' binding. Indeed wash-resistance studies confirm that BU25 does 
not 'pseudoirreversibly' bind to the receptor in C6 cells, while C-CAM and MC-CAM 
do bind in a wash-resistant manner. 
Preliminary molecular modeling studies have shown that all of the 3-alkyl 
substituents have similar molecular volumes. However, the steric hindrance caused 
by a branched chain substituent, such as the isopropyl group of BU25, may preclude 
access to the relevant site on the receptor. Displacement assays were carried out at 
different temperatures in order to increase or decrease membrane fluidity [Remmers 
& Medzihradsky, 1991, Creese et aI., 1975, Zhang & Yang, 1989], in order to 
examine if this had any effect on access of either C-CAM or BU25 to the receptor 
sites. BU25 was unaffected by temperature changes, however the fraction of binding 
to, and the affinity of, <:-CAM for the higher affinity binding site increased when 
experiments were carried out at 37°C. This would suggest a greater ease of access of 
C-CAM to the higher affinity site with increased membrane fluidity. It may also be 
that the binding to the higher affinity site takes a longer time to reach equilibrium, in 
which case an increase in temperature results in quicker attainment of that 
eqUilibrium. This may also be an important point when considering why there is less 
binding to the higher affinity site in guinea-pig brain membranes, . as access to the 
higher affinity site may be more hindered in this preparation. 
Further evidence for irreversible interactions of C-CAM (and presumably the other 
3-alkyl ethers of C-CAM) comes from a time course study of the displacement of 
eH]DAMGO from the Il-receptor in SH-SY5Y cell membranes by C-CAM and 
BU25. Whilst the increase in incubation time has no effect on the displacement of 
eH]DAMGO by BU25, C-CAM becomes increasingly more effective at displacing 
eHlDAMGO from the receptor with time, presumably as a tighter interaction with the 
Il-opioid receptor develops (Fig. 5.20). 
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As can also be seen from the results of the wash resistance study, the a1kylating 
agent ~-FNA does not appear to irreversibly bind to all of the receptors. This 
confirms the findings of Elliott et al., 1994, who proposed that there is a population of 
the Il-receptor resistant to alkylation by this ligand. In order to examine if the site 
available to ~-FNA alkylation was the same site of the receptor for 
'pseudoirreversible' binding of the ethers, the displacement of eH]DAMGO by C-
CAM was carried out after cells had been exposed to 100 nM ~-FNA for I hr. 
However the biphasic displacement was still not resolved, indicating that the ~-FNA­
resistant population still contained both sites available to C-CAM binding. 
A study by Klein & Nelson, [1992], has shown that a series of 3-0-methacrylate 
ethers derived from a number of opioids (naltrindole, naltrexone, oxymorphone, 
etorphine, diprenorphine, and nor-binaltorphimine) undergo substantial 0-
dealkylation to give the parent phenol, accounting for the activity of the ethers 
observed in radioligand binding assays. The authors also tested a saturated ether 
under the same conditions, and showed that it did not possess high affinity for any of 
the 'opioid receptors, presumably due to the inability of the ether to undergo 
dealky~ti!Jn. It is highly unlikely however, that the 3-alkyl ethers of this series could 
undergo nucleophilic attack in the same manner as the 3-0-methacrylate ethers 
described by K1ein & Nelson. It would also be unlikely that O-dealkylation can 
explain the observation of two-site binding as C-CAM itself, which contains the 3-0H 
group, exhibits biphasic binding. 
Results from e 5S]GTPyS assays show that the ethers have limited efficacy. The 
rank order of potency as determined by this assay is slightly different from the order 
obtained from radioligand binding studies, although the ester, CPM, and n propyl 
ethers share the lowest potency in the e5S]GTPyS assay and for both binding sites in 
the radioligand binding studies. The propargyl ether BU23 appears to have reduced 
potency for the second, lower affinity binding site yet has high potency for the first 
binding site and exhibits high potency in the e 5S]GTPyS assay. C-CAM and BU25 
do not stimulate the binding of eSS]GTPyS above basal levels, and BU20 and BU24 
are of very weak agonist character. BUI9 is the most efficacious of the series. The 
overall e 5S]GTPyS data obtained correlates with the data of Husbands et aI., 1998, 
who found that BUI9, BU20, and BU23 were the most potent in the mouse warm 
water tail withdrawal assay. The data of Husbands et al. also shows that BU 19 and 
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BU23 are the most efficacious. MC-CAM is a weak partial agonist in the eSS]GTPyS 
assay, affording only 22 % of the maximal stimulation produced by IO IIM fentanyl. 
This is consistent with previous findings in vivo, where it has been shown that MC-
CAM is of weak partial agonist nature [Woods et aI., 1995, Aceto et aI., 1989, 
Butelman et aI., 1996]. MC-CAM is fully effective in the mouse phenylquinone 
writhing assay but inactive in the mouse tail flick and hot plate tests [Aceto et al., 
1989], and it produces analgesia in the tail withdrawal assay at 50°C, but not 55°C, in 
rhesus monkeys [Woods et aI., 1995]. We can therefore conclude that modification of 
the substituent in the 3-position can have a definite effect on the efficacy of the 
compound, but does not interfere with binding. 
From the above experiments it is clear that the 3-alkyl ethers of C-CAM display 
intriguing binding characteristics, which may provide us with useful information to 
ascertain the mechanisms behind the long-lasting Jl-receptor antagonism produced by 
these ligands. Modification of the 3-substituent appears not only to change the 
efficacy of the compound, but, as is the case with BU25, changing the substituent has 
also had a profound effect on its binding profile relative to the other 3-alkyl ethers of 
C-CAM in this series. Compounds like this with somewhat higher efficacy may 
provide us with useful treatment drugs based upon our hypothesis that a sufficient 
degree of Jl-efficacy followed by a long-lasting Jl-antagonism, probably attributed to 
an irreversible binding interaction such as with buprenorphine, confer upon the 
compound suitable characteristics for use as a pharmacotherapy for the treatment of 
opioid abuse. 
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Figure 5_20 Schematic representation of C-CAM binding to the mu receptor. 
DAMGO binds to sites A and B with equal affinity_ Sites A and B 
could represent two points of attachment for the drug molecule in the 
same binding pocket of the receptor. C-CAM binds to both sites A and 
B, but has a preference for site A, and exerts a non-competitive 
interaction with this site_ C-CAM exerts a competitive interaction with 
site B, resulting in two possible outcomes: 1) DAMGO may remain 
bound, or 2) C-CAM displaces DAMGO and if able to access site A it 
again undergoes a non-competitive interaction_ Hence with time C-
CAM irreversibly binds to more receptors thus reducing the receptor 
number available for DAMGO binding. 
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CHAPTER 6 
CONSTITUTIVE ACTIVITY AT ~- AND o-OPIOID RECEPTORS 
AND THE IDENTIFICATION OF NOVEL INVERSE AGONISTS 
6.1 Introduction 
Opioid receptors belong to the superfarnily of seven transmembrane domain, G-
protein coupled receptors. In this family of receptors signal transduction is achieved 
by agonist occupation of receptors activating one or more G-proteins (See Chapter 1, 
section 1.3). It is now widely accepted that G-protein coupled receptors can exist in 
equilibrium between an active and an inactive state of the receptor [Leff, 1995]. Even 
in the absence of agonist, these receptors can maintain an active conformation and 
display constitutive activity by interacting with the G-protein [Costa & Herz, 1989, 
Lefkowitz et aI., 1993] (Fig. 6.1). Ligands that preferentially stabilize the inactive 
form of the receptor abolish this spontaneous, agonist-independent activity and are 
termed inverse agonists. Neutral antagonists bind to the receptor but do not alter the 
equilibrium between active and inactive states of the receptor. The only known 
opioid receptor inverse agonists are the O-selective peptides rcr 174,864 (N,N-
diallyl-Tyr-Aib-Aib-Phe-Leu-OH) [Costa & Herz, 1989] and the structurally related 
rcr 154,129 (N, N-Bisallyl-Tyr-Gly-GlY-'I'-(CH2S)-Phe-Leu-OH) [Shaw et al., 1982] 
and diallyl-G (N, N-Diallyl-Tyr-D-Leu-Gly-Tyr-Leu-OH) [Georgoussi & Zioudrou, 
1993]. No non-peptide 0- inverse agonists have been identified to date. Moreover, no 
ligand has been discovered to have inverse agonist activity at the 11- or lC-opioid 
receptor, although Wang et al. [1994], have proposed that naloxone exhibits negative 
intrinsic activity in SH-SY5Y cells under conditions of narcotic tolerance. The 
observation that clocinnamox (C-CAM, see Chapter 5) gave a dose-dependent 
reduction in e5S]GTPyS binding in rat C6 glioma cells transfected with the cloned rat 
o-receptor led us to investigate constitutive activity and inverse agonism in this cell 
line and also in C6 glioma cells transfected with rat cloned l1-opioid receptor. To 
study constitutive activity we have used the agonist-independent stimulation of 
e5S]GTPyS binding in the absence of sodium ions to provide a higher level of 
spontaneous activity [Costa & Herz, 1989, Szekeres & Traynor, 1997]. The findings 
confirm constitutive activity associated with the cloned o-receptor and identify C-
CAM and 7-benzylidenenaltrexone (BNTX), a ol-receptor antagonist [Portoghese et 
aI., 1992], as two novel non-peptide inverse agonists. Under similar conditions the 11-
receptor exhibits limited constitutive activity. 
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A A 
+ L + 
R .. ~ R* 
KA 1i li KA* 
AR .. ~ AR* 
(resting) (active) 
Figure 6.1 The two-state model according to Leff [1995]. The receptor exists in 
equilibrium between inactive (R) and active (R *) states. The equilibrium 
constant, L, determines the distribution of receptors between the two 
states in the absence of agonist. Interaction of an agonist, A, will shift the 
equilibrium in favour of one of the two states. If it has higher affinity for 
R *, the ligand will be an agonist, but if it has higher affinity for R, the 
resting state, it will be an inverse agonist. 
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6.2 Results 
6.2.1 Saturation binding of r3H]diprenorphine to C6 glioma cell membranes 
Saturation binding experiments were carried out using eHldiprenorphine in order to 
determine the receptor number in C61i and C61l cells. Bmax values and dissociation 
constants are given in Table 6.1 and representative saturation binding plots are shown 
in Figs. 6.2 and 6.3. 
C61i 
C61l LOW 
C61l HIGH 
Bmax 
Cfmols mg·1 protein) 
728 ± 18 
420± 94 
1733 ± 83 
KDCnM) 
0.46 ±0.05 
0.24±0.1l 
0.18 ± 0.10 
Table 6.1 Bmax and KD values obtained from the saturation binding of 
eHldiprenorphine to membranes prepared from C61i cells and C61l cells expressing 
both high and low receptor number. Values represent mean ± S.E.M for three 
experiments carried out in duplicate. 
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Figure 6.2 Representative graph showing saturation binding of CHldiprenorphine to 
C60 cell membranes. Bmax = 732 fmols mg· 1 protein and KD for 
diprenorphine = 0.39 nM. 
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Figure 6.3 Representative graphs showing saturation binding of eHldiprenorphine to 
C61l cell membranes (A) = with lower receptor number, (B) = with higher 
receptor number. Bmax = 306 and 1650 fmols mg" protein respectively, 
and KD values for diprenorphine = 0.13 and 0.28 nM respectively. 
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6.2.2 Constitutive activity of cloned opioid receptors expressed in C6 glioma cells. 
In the presence of Na+ ions the basal binding of eSS]GTPyS to membranes from C6/) 
cells was 41.3 ± 1.8 fmols mg'\ protein (Fig. 6.4). This increased to 72.3 ± 9.5 fmols 
mg'\ protein when Na+ ions were replaced with K+ ions. Basal binding of eSS]GTPyS 
to C611 cell membranes was also increased from 22.4 ± 0.1 to 37.1 ± 1.8 fmols mg'\ 
protein. 
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Figure 6.4 Agonist independent basal eSS]GTPyS binding in C611 and /) cell 
membranes in the presence of either Na+ or K+ ions. * P < 0.05, ** P < 
0.01, significantly different from basal binding in the presence of Na+ 
ions, unpaired Students' t-test. 
Treatment of C6/) cells with pertussis toxin (PTX) reduced basal levels of 
eSS]GTPyS binding by 51.9 ± 6.1 fmols mg'\ protein to 20.4 ± 3.9 fmols mg'\ protein 
confirming the presence of constitutively active receptors activating G;/Go proteins 
(Fig. 6.5). In contrast PTX treatment reduced basal eSS]GTPyS binding in C6 wild-
type cells by only 8.6 ± 3.1 fmols mg'\ protein, to 17.30 ± 1.70 fmols mg'\ protein. A 
similar low reduction was observed in C611 cells, regardless of receptor expression 
level. In the clone expressing a receptor number of 427 fmols mg'\ protein, PTX 
treatment reduced the basal eSS]GTPyS binding by 10.0 ± 3.5 fmols mg'\ protein, and 
\0\ 
in the clone expressing the receptor number of 1703 fmols mt' protein the reduction 
in basal binding was 14.6 ± 3.3 fmols mg" protein (Fig. 6.5). The reduction in basal 
binding in both C6 clones was not statistically significantly different from the 
reduction in wild-type C6 cells (Students' unpaired t-test). One-way ANOVA to 
compare basal eSS]GTP'yS binding in C6Jl cells of low and high receptor expression 
number following PTX treatment also showed no statistically significant differences 
between the means of each clone. 
** 
I I control 
~ PTX-treated 
Figure 6.5 Basal eSS]GTP'yS binding in membranes prepared from C6 glioma cells 
pre-treated with pertussis toxin (lOO ng mr', 24 hr). Values represent the 
mean ± S.E.M. of at least three experiments performed in duplicate. ** P 
< 0.0 I, significantly different reduction of basal binding compared to that 
seen in C6 wild-type cells, Students' unpaired t-test. 
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6.2.3 Identification of non-peptide inverse agonists at the &receptor 
The previously reported peptide inverse agonist ICI 174,864 inhibited basal 
e5S]GTPyS binding by 11.3 ± 0.3 fmols mg"1 protein at a concentration of I j.LM (Fig. 
6.6). 
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Figure 6.6 Inhibition of e5S]GTPyS binding by various antagonists at the cloned 8-
opioid receptor in membranes prepared from C60 cells. Values represent 
mean ± S.E.M. for at least three experiments performed in duplicate. 
Investigation of the antagonist nature of various compounds revealed that 7-
benzylidenanltrexone, (BNTX), a 81 rec'eptor antagonist, and the 14-cinnamoylamino 
morphinone clocinnamox, (C-CAM), were able to inhibit the basal binding of 
e5S]GTPyS in C68 cell membranes by 10.0 ± 3.1 and 20.3 ± 3.4 fmols mg- I protein 
respectively. The partial l1-agonist buprenorphine, the li-selective antagonist 
naltrindole, and the non-selective antagonist naloxone all acted as neutral antagonists 
in this system (Fig. 6.6). 
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Figure 6.7 Dose-dependent inhibition of e5S]GTPyS binding by the peptide ICI 
174,864 in membranes prepared from C60 cells. All values represent 
mean ± S.E.M. for at least three experiments performed in duplicate. 
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Figure 6.8 Dose-dependent inhibition of e5S]GTPyS binding by C-CAM in 
membranes prepared from C60 cells. Values represent mean ± S.E.M 
from at least three experiments carried out in duplicate. 
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Figure 6.9 Dose-dependent inhibition of eSS]GTPyS binding by BNTX in membranes 
prepared from C61i cells. Values represent mean ± S.E.M. for at least 
three experiments carried out in duplicate. 
BNTX C-CAM ICI 174,864 
~C60 
DC6WT 
~C61l 
Figure 6.10 Inhibition of eSS]GTPyS binding by BNTX, C-CAM and lCl 174,864 
(all 1 1lM) in C61i, C61l and C6 wild-type membranes. Values 
represent mean ± S.E.M. for at least three experiments performed in 
duplicate. **p < 0.01, *p< 0.05, comparing inverse agonists in C61i to 
C6WT and C61l, one way analysis of variance. 
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Figure 6.11 Reversal of inverse agonist activity by the 0- neutral antagonist 
naltrindole (10 ~) in C60 cell membranes. Values represent mean ± 
S.E.M for at three experiments performed in duplicate. * P < 0.05, 
Students' unpaired Hest. 
No inhibition of basal eSS]GTPyS binding was observed in membranes prepared from 
wild-type C6 cells or C6/l cells (Fig. 6.10). Concurrent addition of the O-opioid 
neutral antagonist naltrindole blocked the inverse agonist response of BNTX, C-
CAM, and lCl 174,864 (al1 I ~) in C60 cel1 membranes (Fig. 6.11). Basal 
eSS]GTPyS binding values in the presence of naltrindole were 2.7 ± 2.4, -2.0 ± 4.0, 
and 2.0 ± 2.1 fmols mg- I protein for BNTX, C-CAM, and ICI 174,864 respectively. 
It is well documented that the addition of NaCI and guanine nuc1eotides to binding 
assay buffer serves to uncouple the G-protein from the receptor resulting in a low 
affinity form of the receptor [Pastemak et al., 1975, Childers & Snyder, 1980]. In this 
study the Ki values for the inhibition of eH]naltrindole binding to C60 cel1 
membranes were obtained for ICI 174, 864, C-CAM, and BNTX with and without 
NaCI and GppNHp, a GTP analogue, present in the binding buffer (Table 6.\). To 
calculate the affinities a Ko of 0.12 nM for eH]naltrindole was used (A. Alt, our 
laboratory, personal communication). Addition of NaCI and GppNHp afforded a 7-
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fold leftward shift in the competition curve was observed for IC! 174,864 (Fig. 6.12). 
As seen in Chapter 5 with studies at the I.l-receptor, C-CAM also displayed a biphasic 
binding profile for the displacement of eHlnaltrindole from C60 cell membranes. 
Addition of NaCI and GppNHp afforded a 5-fold leftward shift of the lower affinity 
site of the competition curve (Fig. 6.13), but the leftward shift of the higher affinity 
site was much less pronounced (lA fold), and was not significant. The Ki value for 
the inhibition of eHlnaltrindole binding by BNTX was unchanged (Fig. 6.14). 
Drug Ki (nM) in Tris Ki (nM) in Tris KiL/KiH 
Buffer Buffer + NaCl 
+ GppNHp 
ICI174,864 266±9.0 37.0±9.9 7.2 
C-CAM 0.37 ± 0.28 pM 0.26 ± 0.13 pM 1.4 
1.3 ± 0.05 0.25 ±0.1O 5.2 
BNTX 1.6 ± 0.3 2.1 ± 1.0 0.8 
Table 6.2 Ki values for the inhibition of eHlnaItrindole binding (0.2 nM) to C60 
cell membranes, with and without the addition of NaCI and the non-
hydrolyzable GTP analogue, GppNHp to the assay buffer. 
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Figure 6.12 The displacement of eHJnaltrindole (0.2 nM) by ICI 174, 864 in C60 cell 
membranes, with and without NaCI and GppNHp in binding buffer. 
Values represent mean ± S.E.M of three experiments performed in 
duplicate. 
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Figure 6.13 The displacement of eHJnaltrindole by C-CAM in C60 cell membranes, 
with or without NaCI and GppNHp to the assay buffer. Values represent 
mean ± S.E.M for three experiments performed in duplicate. 
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Figure 6.14 The displacement of eHJnaltrindole by BNTX in C60 cell membranes, 
with and without NaCI and GppNHp in the assay buffer. Values 
represent mean ± S.E.M for at least three experiments performed in 
duplicate. 
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6.3 Discussion 
Previous literature suggests that there is a degree of constitutive activity associated 
with the O-opioid receptor, due to the ability of the peptide ICI 174,864 to inhibit 
basal GTPase activity [Costa & Herz, 1989, Mullaney et al., 1996] and enhance 
forskolin-stimu1ated cAMP accumulation [Chiu et aI., 1996]. However, tools to 
investigate constitutive activity at O-opioid receptors are scarce and as yet there have 
been no reports of similar findings with the l1-opioid receptor. An initial observation 
in our laboratory that c1ocinnamox (C-CAM) (See Chapter 5) appeared to exhibit 
negative intrinsic activity at the cloned O-receptor, but not at the cloned l1-receptor, in 
rat C6 glioma cells led us to evaluate the level of constitutive activity associated with 
these receptors and compare it to the level of constitutive activity in wild-type rat C6 
glioma cells. In order to improve chances of observing constitutive activity 
experiments were carried out in GTPyS binding buffer containing K+ ions instead of 
Na+ ions. It has been shown previously [Costa & Herz, 1989] that the inverse agonist 
effect of ICI 174,864 on GTPase activity is much more pronounced in buffer in which 
the Na+ ions had been replaced by K+. Constitutive activity occurs when receptors 
exist in the active (R *) state, and therefore can couple to G-proteins in the absence of 
agonist. Thus, because Na+ reduces basal eSS]GTPyS binding by lowering the 
affinity of 'empty' opioid receptors for G-protein, it serves to reduce the constitutive 
activity of the receptor and therefore masks any observable inverse agonist activity. 
Substitution of Na+ ions with K+ ions thus provides a higher level of spontaneous G-
protein coupling [Costa & Herz, 1989, Szekeres & Traynor, 1997], hence enabling the 
observation of any reduction in agonist-independent receptor activation. 
Treatment of C6 wild-type cells with pertussis toxin (PTX) alone reduced basal 
binding of eSS]GTPyS suggesting a tonic level of G-protein activation. However in 
C6/i cells the reduction in basal levels by PTX was much more pronounced 
confirming an increased level of constitutive activity associated with the O-receptor. 
In contrast C6 cells expressing the l1-opioid receptor showed a similar small reduction 
of basal eSS]GTPyS binding by PTX as seen with wild-type cells, suggesting a lack of 
constitutive activity associated with the l1-opioid receptor. A high receptor expression 
level is thought to lead to constitutive activity [Lefkowitz et al., 1993, Samama et al., 
1993] due to enhanced collision probability of R * with G [Stickle & Barber, 1992]. 
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However, the lack of constitutive activity observed at the !!-receptor does not appear 
to be due to receptor expression level, as similar levels of basal eSS]OTPyS binding 
were seen with C6!! cells expressing a higher receptor number. The PTX-induced 
reduction in basal binding in wild-type and C6!! cells must be due to the presence of 
other non-opioid 0;100 coupled receptors. 
In addition to ICI 174,864, the irreversible !!-antagonist cIocinnamox (C-CAM) 
and the 01 selective antagonist 7-benzylidenenaltrexone (BNTX) also acted as inverse 
agonists in C60 cell membranes affording dose-dependent reduction in eSS]OTPyS 
binding. The dose-response curve for C-CAM was shallow which may reflect its 
binding to a higher affinity site of the receptor as observed in competition binding 
assays at the O-receptor expressed in C6 glioma cells, and the !!-opioid receptor in 
SH-SYSY cell membranes, C6!! cell membranes, and guinea-pig brain membranes 
(see discussion in chapter S). The inverse agonist activity of these compounds was 
not observed in wild-type or C6!! cell membranes, suggesting that the response was 
mediated via the o-opioid receptor. This was supported by the reversal of inverse 
agonist activity by the 0- antagonist naItrindole. 
None of the inverse agonists were able to inhibit basal eSS]GTPyS binding to the 
same extent as pre-treatment of cells with pertussis toxin. This is due to the presence 
of non-opioid constitutively active receptors, as seen by PTX-reduction of activity in 
the wild-type cells, but also suggests that the present compounds can only partially 
reverse constitutive activity at the B-receptor, i.e. they are partial inverse agonists. 
Szekeres & Traynor [1997] reported similar findings using ICI 174,864 on 
membranes prepared from NO 108-IS neuroblastoma x glioma hybrid cells. However, 
Mullaney et al. [1996] reported that in rat I fibroblasts expressing the cloned mouse 0 
receptor, ICI 174,864 did inhibit basal binding of eSS]OTPyS to the same extent as 
pre-treatment of cells with pertussis toxin. The authors concluded that ICI 174,864 
was an inverse agonist of high negative intrinsic efficacy. 
According to the two state model of receptor activation, [Leff, 1995, Fig. 6.1], 
inverse agonists preferentially stabilise the inactive conformation of the receptor. 
Therefore, one would predict that these compounds would have a higher affinity for 
the uncoupled state of the receptor. It was hypothesised that BNTX, C-CAM, and ICI 
174,864 would have higher affinity for the B-receptor when uncoupled from 0-
III 
protein. Competition binding assays were performed with the addition of NaCI and 
the non-hydrolyzable GTP analogue, GppNHp, to the buffer. The addition of Na+ 
ions and guanine nucleotides alters the equilibrium between R and R * towards the 
inactive form of the receptor (R). Thus the affinity of an agonist for the receptor is 
decreased whereas the affinity of an antagonist is unchanged, and if our hypothesis is 
correct, the affinity of an inverse agonist would be increased. This held true for both 
C-CAM and ICI 174,864. Indeed Appelmans et al. [1986], have shown that the 
affinity of ICI 174,864 for the O-opioid binding site is increased 8 - 16 fold upon 
addition of 25 mM NaCI to the reaction buffer. However, the affinity of BNTX for 
the receptor did not change. This suggests that the ability of BNTX to inhibit 
e5S]GTPyS binding does not relate to its affinity for the O-receptor under conditions 
promoting coupled (active) and uncoupled (inactive) forms of the receptor. Additional 
evidence for this comes from other studies using dopaminergic systems, where it was 
found that several inverse agonists at the 0 3 receptor, including haloperidol, bound 
with the same affinity to untreated and PTX treated 0 3 receptors [Malmberg et al., 
1998]. Together these findings question the hypothesis that inverse agonism arises 
due to greater affinity of a ligand for uncoupled (R), as opposed to coupled (R *), 
forms of the receptor. 
Studies of inverse agonism at the O-receptor have also been extended to include 
whole cell preparations. Merkouris et al. [1997], presented some interesting data 
concemmg the effects of ICI 174,864 on cAMP accumulation in intact rat-1 
fibroblasts. Prior treatment of cells with PTX inhibited, but did not mimic, the effects 
of ICI 174,864 on the enhancement of forskolin stimulated cAMP. Similar results 
were reported by Chiu et al [1996] using human embryonic kidney cells expressing 
the cloned O-receptor. If the receptor exists in a constitutively active, coupled state, 
then one would expect that forskolin is having to work against a tonic inhibition of 
cAMP accumulation. Therefore PTX treatment should abolish this tonic inhibition, 
thus allowing an apparent greater stimulation of cAMP by forskolin. However this 
was not seen. This again questions the hypothesis that constitutive activity is 
dependent upon an active (coupled) form of the receptor, and, together with the 
binding data for BNTX and the study using haloperidol, this suggests that perhaps 
other mechanisms are in place, for example tonic activation arising from the G-
protein itself. 
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It would be of considerable interest to examme more closely the possible 
physiological consequences of administration of these opioid inverse agonists in vivo. 
C-CAM has been well characterised as a long-lasting 'pseudoirreversible' opioid 
antagonist devoid of agonist properties in vivo [Corner et al., 1992, Zemig et aI., 
1994, 1996]. However Zemig et al. [1995], reported that C-CAM caused 
hyperalgesia in mice in the acetic acid- induced writhing assay. If C-CAM were able 
to produce an inverse agonist effect in vivo, one might expect hyperalgesia to occur. 
Administration of C-CAM would be expected to shift the equilibrium of the 6-opioid 
receptors to an inactive state hence reducing the tonic level of G-protein activation, 
thereby reducing the baseline level of 6-receptor mediated analgesia .. 
The therapeutic benefit of inverse agonists is largely unknown. Speculation arises 
as to whether inverse agonists may be of use in the treatment of certain diseased states 
occurring from constitutively active receptors as a result of point mutations in the 
genome [Milligan et al., 1995, Spiegel et al., 1993]. For example precocious puberty 
has been shown to occur as a result of constitutive activation of adenylate cyclase by 
the luteinizing hormone receptor, and mutations of the thyrotropin receptor are 
thought to be responsible for hyperfunctioning thyroid adenomas. To date there have 
been no reports of disease states arising from mutations of opioid receptors, therefore 
it would seem that inverse agonists at opioid receptors would have no clinical utility. 
However, the presence, or lack of, constitutive activity at opioid receptors and the 
characterisation of opioid inverse agonists warrants further investigation in order to 
further understand the physiological relevance of tonic opioid receptor/G-protein 
interactions. 
The results shown indicate that constitutive activity within the opioid receptor 
family may be dependent upon receptor subtype. The lack of constitutive activity at 
the J.1-opioid receptor, even under optimum conditions of replacing Na+ ions with K+ 
ions, is intruiging but caution must be exercised as experiments have only been 
carried out on the 6-receptor expressed in C6 glioma cells, albeit at two different 
expression levels. However, it may explain why, when so many l1-ligands are known 
of other chemical types, including the competitive antagonists such as naltrexone, 
naloxone, cyprodime, CTOP, CT AP etc, that no J.1-inverse agonists have been 
discovered to date. 
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CHAPTER 7 
OVERVIEW 
OVERVIEW 
The advent of buprenorphine has provided researchers with a useful lead to develop 
novel pharmacotherapies for the treatment of opioid abuse. The mixed 
agonist/antagonist actions of buprenorphine, together with its ability to attenuate the 
effects of any subsequently self-administered opioid, appear to offer significant 
advantages over currently existing therapies such as the full l1-agonists methadone 
and LAAM. More recently, there have been preliminary reports that the long-lasting 
14-cinnamoylamino codeinone, methoclocinnamox (MC-CAM), may be useful as a 
treatment drug. In a manner similar to buprenorphine, MC-CAM exhibits initial 
agonist activity followed by a long-lasting antagonism of morphine. 
The characteristic bell-shaped dose-response curve produced by buprenorphine in 
vivo is probably an important contributing factor to the overall safety profile of the 
drug. An investigation into the antinociceptive actions of buprenorphine using the rat 
warm water tail withdrawal assay at 50°C revealed that the unique bell-shaped dose-
response curve of buprenorphine is time-dependent. Higher doses of buprenorphine 
show a rapid peak of near-maximal antinociception within 15 min of administration. 
This is followed by an equally rapid decline in antinociceptive effect. In contrast 
lower doses show a slow onset and offset of antinociceptive action. Therefore if the 
anti nociceptive measure is recorded 15 min after administration of buprenorphine, a 
bell-shaped dose-response curve is not observed. The possibility of receptor 
desensitization following administration of higher doses of buprenorphine was 
examined, but the results obtained suggest this not to be the case. Although the 
subsequent actions of buprenorphine were blocked following pre-treatment for 1.5 hr 
with a high (1.0 mg kg-I) dose of buprenorphine, the antinociceptive effect of the full 
l1-agonist fentanyl was unchanged under similar conditions. Since buprenorphine 
binds very tightly to the l1-opioid receptor, this may reflect different binding 
requirements of fentanyl and buprenorphine for the l1-receptor, and indeed there is 
evidence to support this [Heerding et al., 1994]. It is clear from the data obtained that 
the mechanism behind the bell-shaped dose-response is of great complexity. The 
inability of naltrexone to shift both the ascending and descending phases of the curve 
contradicts previous literature reports, however this may be explained in terms of 
cumulative dosing paradigms in the current investigation. In order to attempt to 
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explain the mechanism behind the unique biphasic dose-response curve, a model has 
been proposed whereby buprenorphine initially binds to the Jl-opioid receptor 
producing agonist actions, and then over time is able to form a tight lipophilic 
interaction with the receptor, thus inducing an antagonist conformation and inhibiting 
further agonist activation. Indeed this would agree with evidence that approximately 
50 % of buprenorphine still remains bound to the receptor [Boas & Villiger, 1985]. 
Although buprenorphine is the most promising alternative to methadone or LAAM 
for the treatment of heroin abuse, the degree of reinforcing effect may not be 
sufficient enough to maintain the most experienced of addicts in a treatment program. 
The morphinan-pyrrolidine derivative, BUn, appears to offer that quality. In 
radioJigand binding assays using C6 glioma cells transfected with the Jl-opioid 
receptor, BUn displayed high affinity for the Jl-receptor and was a full agonist in the 
C5S]GTPyS assay affording 116 % of the fentanyl response. In vivo BUn produced 
dose-dependent antinociception in the mouse warm water tail-withdrawal assay and 
was approximately 400 times more potent than morphine. Similar results were 
obtained in the acetic-acid induced writhing assay. Unlike buprenorphine however, 
the agonist effects of BUn were readily reversed by the non-selective antagonists 
naloxone and naltrexone. Administration of a high dose of BUn afforded long-
lasting antinociception after which time antagonism of morphine was observed in 
both tail withdrawal and writhing assays. In the writhing assay a maximal dose of 
morphine was still fully antagonized after 6 days. Thus, BUn is a highly efficacious 
Jl-opioid agonist with subsequent antagonist properties and as such represents an 
important lead for the development of therapies for the treatment of opiate abuse. 
The reports that MC-CAM may also be useful as a treatment drug has led to the 
development of 3-alkyl ethers of MC-CAM. It has been shown that variation of the 
substituent of the 3-position offers a wider range of efficacies without altering the 
long-lasting antagonist properties of this series of compounds. This was confirmed in 
C5S]GTPyS assays using membranes prepared from SH-SY5Y human neuroblastoma 
cells. An investigation into the binding profile of the 3-alkyl ethers using SH-SY5Y 
and C61l cells revealed that with the exception of the iso-propyl ether BU25, all of 
these drugs bound to the Il-opioid receptor in a biphasic manner. Experiments carried 
out to determine the mechanism behind this unusual phenomenon showed that the 
biphasic binding was unaffected by the addition of NaCl to the assay buffer, hence the 
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two components of binding did not represent a single receptor site existing in high and 
low affinity states. Pre-treatment of cells with the alkylating agent I3-FNA also did 
not change the binding profile, suggesting that the population of cells previously 
shown to be resistant to I3-FNA alkylation still contained both sites available to C-
CAM binding. The degree of biphasic binding appeared to be system dependent, and 
incubation for longer periods of time or at an elevated temperature increased the 
fraction of binding to the higher affinity site. It is suggested that thebiphasic binding 
exhibited by the series of 3-alkyl ethers represents two components of binding to the 
Il-opioid receptor; a reversible, lower affinity component and an irreversible, higher 
affinity component. The steric hindrance caused by the bulky iso-propyl substituent 
of BU25 may prevent it accessing the higher affinity site and thus this compound· 
shows monophasic binding. Clearly modification of the 3-substituent has a profound 
effect on the overall pharmacological profile of these compounds. 
The morphinone derivative of MC-CAM, c1ocinnamox (C-CAM), is an antagonist 
devoid of agonist activity. It too displays biphasic binding not only at the Il-receptor, 
but also at the &-opioid receptor. Surprisingly, studies of eSS]GTPyS binding in C61l 
and C68 cells revealed that C-CAM acted as an inverse agonist at the &-, but not the 
Il-receptor. This prompted an investigation into constitutive activity at these opioid 
receptors, where it was discovered that constitutive activity was present at the &-
receptor, but not at the Il-receptor. This may explain why, to date, no inverse agonists 
have been shown for the Il-receptor. Moreover it was discovered that· the 8, 
antagonist 7-benzylidenenaltrexone (BNTX) also acted as an inverse agonist at the &-
receptor in C6 glioma cells. Together with C-CAM these are the first non-peptide 8-
receptor inverse agonists to be found. 
In conclusion, the characterization of buprenorphine and other long-lasting opiates 
has provided a useful lead to the development of alternative treatment drugs. The 
rnorphinan pyrrolidine derivative BUn appears to be a useful candidate for further 
evaluation. Studies of MC-CAM and its derivatives have revealed a unique binding 
profile related to their ability to form long-lasting interactions with the Il-receptor. 
Although the exact mechanisms behind the 'pseudoirreversible' interactions of 
buprenorphine and the 14-cinnamoylamino compounds· have not been fully 
elucidated, it is clear that this aspect of their pharmacology is of great importance in 
their profile as a potential treatment drug. 
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